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ABSTRACT 
 
Human cytomegalovirus (HCMV) causes morbidity and mortality in congenitally infected 
newborns, transplant recipients, and AIDS patients. Currently, there is no approved CMV 
vaccine to address these issues. In an effort to develop an alternative treatment to CMV we tested 
our hypothesis that heparan sulfate binding D-peptides would be effective against multiple 
HCMV strains in vitro and it would be effective in vivo against murine CMV (MCMV) (Chapter 
1).  We show that the D-peptide is able to reduce CMV infection in vitro and in vivo. Another 
approach to combating CMV infections is to neutralize pathogenic factors that contribute to 
CMV spread and/or pathogenesis.  HCMV contains genes with homology to human immune 
modulators.  These genes have been implicated in establishing lifelong HCMV latency.  One of 
these factors is an HCMV expressed viral chemokine (vCXCL-1).  CXCL-1 binds to chemokine 
receptors expressed on host immune cells.  In order to understand how vCXCL-1 is involved in 
CMV pathogenesis we used recombinant MCMV overexpressing chimpanzee CMV vCXCL-1 
(vCXCL-1CCMV) and murine CXCL-1 (KC).  We hypothesized that CMV encodes vCXCL-1 to 
aid in viral dissemination (Chapter 2).  In contrast we found that over expression of CXC 
chemokines recruits innate immune cells to the site of infection and primary dissemination 
organs leading to a dissemination blockade.  vCXCL-1 is encoded by the HCMV UL146 gene, 
which has shown variation among clinical isolates. This variation may attribute contribute to 
varying clinical outcomes of HCMV infections. We hypothesize that variation in vCXCL-1 leads 
to differential activation of neutrophils (Chapter 3). Throughout this thesis we have explored 
how the virus spreads, causes disease and a potential peptide that could be used to prevent the 
initial CMV infection.  
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  INTRODUCTION  
Chemokines and chemokine receptors 
Chemokines are small cytokine-like proteins involved in chemotaxis, positioning and 
activation of leukocytes. This function is important for immune cell development and the 
generation of humoral and cellular responses [1].  There are four chemokine classifications based 
on the terminal cysteine residue spacing: C (γ subfamily), CC (β subfamily), CXC (α subfamily), 
CX3C (δ subfamily). These chemokine bind to ~20 chemokine receptors which play a role in 
modulating the immune response by signaling, internalizing or degrading the chemokine ligands 
[2-4].  Chemokine signaling is mediated through rhodopsin class G-protein coupled receptors 
(GPCRs) and G-protein independent atypical chemokine receptors [1].  GPCRs are composed of 
seven-transmembrane helical regions connected by alternating extracellular loops and 
intracellular loops.  Disulfide cysteine pairs connect the N-termini and the seventh α helix. The 
third α-helix and second extracellular loop are conserved across CXC chemokine receptors, 
which contributes to their CXC chemokine ligand specificity [5].  Residues at the N-terminus of 
the chemokine receptors are required for ligand binding and subsequent receptor signaling [6-
11].  Truncations at the N-terminus of the receptor disrupt chemokine mediated signaling due to 
inefficient ligand binding [7, 8, 10-12].  Residue changes or deletions in distal parts of the 
receptor also alter binding specificity and affinity [13]. Variability within each class of 
chemokine receptors and ligands contribute to binding specificity and subsequent signaling 
pathways.  These variations will be discussed below. 
 Within each chemokine classification there are specific ligands that bind to a cognate 
chemokine receptor on different cells.  This specificity facilitates its ability to induce different 
chemokine-mediated signaling. Within the γ subfamily there are two C chemokines, XCL1 and 
XCL2, which are also known as lymphotactin α and β [14-17]. Lymphotactin α and β 
chemokines bind to XCR1 and XCR2, respectively. These chemokines attract neutrophils, T 
lymphocytes and B lymphocytes in inflammatory diseases such as Crohn’s Disease [18].   
There are 28 ligands within the CC chemokine subfamily.  CC chemokines affect a wide 
variety of cell types including dendritic cells, monocytes, basophils, and eosinophils [13, 19]. 
CCL2 (monocyte chemoattractant protein; MCP-1) is a well characterized CC chemokine that 
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plays a role in monocyte mobilization [20-24].  Epithelial and endothelial cells can produce 
CCL2, especially during inflammation or tissue damage that occurs during atherosclerosis [25-
27].  CCL2 also binds to CCR2 or CCR4 on CD4+ and CD8+ T lymphocytes, which elicits the 
adaptive immune response after the initial innate immune response [28-30]. Dendritic cells, 
macrophages and mast cells produce CCL3 and CCL4 (macrophage inflammatory protein 1- α 
and β; MIP-1 α and β) [31, 32]. CCL3 and CCL4 bind to CCR5 on monocytes, NK cells, and 
CD8+ T cells [33, 34].  TNF, released during inflammatory processes, induces CCL3 leading to 
an influx of neutrophils and macrophages to the site of inflammation [35, 36].  CCL5 (RANTES) 
also binds CCR5 on eosinophils and T lymphocytes [37].  More recent studies suggest CCL5 is 
associated with progression of breast cancer because it increases inflammation and eosinophilia 
in the tumor microenvironment [38].  Some CC chemokines like CCL19 and CCL21 are 
involved in T lymphocyte homing [39].   CCR7, which is upregulated on CD4+ and CD8+ T 
lymphocytes during inflammation, binds CCL19 and CCL21 to initiate the adaptive immune 
response [40-42]. The NH2 terminus of CCR2, CCR3, and CCR5, is important for chemokine 
recognition of their respective CC chemokine ligand binding [43-47].  Another characteristic of 
CC chemokine receptors is extensive tyrosine glycosylations that increase CC chemokine 
affinity [48-54]. Heterodimerization can also affect chemokine receptor signaling. For example, 
CCR2 can heterodimerize with CCR5 if co-expressed in CD8+ T lymphocytes [55].  In this 
instance CCR5 ligands, CCL3 and CCL4, can block CCR2 signaling. Likewise, the CCR2 ligand 
can block signaling through CCR5. This points to the complexity of signaling from chemokine 
receptors and their ligands.  
CXC chemokines fall into two categories, those with the amino acid motif of glutamic 
acid-leucine-arginine (ELR) and non-ELR [13].  The ELR motif is necessary to attract 
neutrophils [56].  The ELR CXC chemokines, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, 
CXCL7 and CXCL8, bind to either CXCR2 alone or both CXCR1 and CXCR2.  These receptors 
are found on neutrophils, dendritic cells, NK cells and γδ T lymphocytes [13, 57-61].  CXCR2 
has a high affinity for CXCL1 (Groα) and CXCL8 (IL-8) [62].  The CXCL1 ligand is expressed 
on the luminal surface of the endothelium and participates in neutrophil rolling and adhesion by 
binding to CXCR2 on those cells [63].  CXCL8 is important for neutrophil recruitment and 
sustainment during acute inflammation [64].  Furthermore studies have shown CXCL8 
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upregulates expression of β2-integrins on neutrophils, which facilitate migration from the 
vasculature into inflamed tissues [65-67].  Non-ELR CXC chemokines include CXCL4, CXCL9, 
CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, and CXCL15.  These chemokines are 
involved in the recruitment of a variety of inflammatory cells.  CXCL9, (MIG), CXCL10 (IP-10) 
and CXCL11 (I-TAC) bind to CXCR3 on monocytes, NK cells, NKT cells and T lymphocytes 
[68-73]. The expression of CXCR3, along with CCR5, on CD8+ T lymphocytes is a hallmark of 
memory cell generation [74-76].  It is thought that CXCR3 is used to traffic CD8+ T 
lymphocytes into infected or inflamed tissues [75].  Often during inflammation or infection IFN-
γ produced by CD4+ T lymphocytes and NK cells stimulates CXCL9 and CXCL10 production 
which exacerbates the inflammatory response [71-73, 77, 78].  CXCL12 binds to CXCR4 on B 
lymphocytes during proliferation [79] then induces B lymphocyte migration into the secondary 
lymphoid organs [39].  Recently CXCR1 and CXCR4 were shown to be structurally similar [5, 
80].  Both CXCR1 and CXCR4 contain charged residues near the membrane surface that bind to 
basic residues found in their ligands [43].  They differ from previously characterized GPCRs in 
that a kink causes a directional change of one of the transmembrane helices.  However the 
CXCR1 receptor is longer than the CXCR4 receptor because of the H8 helix present right before 
the C terminus.  The H8 helix contributes to the extension of CXCR1.  This small difference in 
length could correlate to their binding affinities for their respective chemokines, i.e. CXCL-1 and 
CXCL-8 versus CXCL12.  The NH2-terminal extracellular loops are important for ligand 
specificity.  Exchange of this region between CXCR1 and CXCR2 changes the ligand specificity 
between the two [9].  Although there are similarities between chemokine receptors within and 
among classifications, subtle differences in structure and residues alter ligand binding 
significantly.  
CX3CL1 (fractalkine) is the only ligand in the CX3C subfamily.  CX3CL1 is unique in 
that it contains a mucin-like stalk with a chemokine domain at its extracellular end.  The stalk 
like structure of CX3CL1 allows leukocytes to adhere and travel along the endothelium [81, 82]. 
The chemokine domain can be cleaved from its stalk and activate monocytes and T lymphocytes 
[81-83].   CX3CR1 is expressed on patrolling, or anti-inflammatory monocytes, NK cells, and 
CD8+ T lymphocytes [58, 59, 84-86].  CX3CL1 is highly expressed in atherosclerotic plaques 
[87, 88] suggesting it causes an influx of monocyte/macrophage populations involved in plaque 
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formation. CX3CL1 is also associated with inflammation in adipose tissue and functions as an 
adipokine in obese and diabetic patients [89, 90]. Because CX3CL1 is a potent activator of 
monocytes it has the potential to induce an inflammatory response contributing to atherosclerotic 
plaque formation.  
Chemokine Signaling  
Upon ligand binding, GPCRs undergo a conformational change.  These changes trigger G 
proteins inside the cell to begin the first intracellular signaling events.  G proteins are made of 
hetero trimeric proteins with: α, β, γ, and sometimes δ, subunits [91, 92]. Conformational 
changes in GPCRs upon chemokine binding results in the exchange of guanine diphosphate 
(GDP) for guanine triphosphate (GTP) on the α-subunit.  The GTP bound α-subunit dissociates 
from its βγ subunits and remains in an active state until the terminal phosphate is hydrolyzed and 
the α-subunit returns to its inactivate-GDP bound state [93-96].  The α-subunits are Gαs, Gαi/o, 
Gαq/11 and Gα12/13.  These subunits are important for transducing the external chemokine signal to 
the downstream signaling proteins in the cytoplasm.  Gαs activates adenylate cyclase (AC), which 
acts on cyclic AMP (cAMP), leading to mitogen activated protein kinase (MAPK) and protein 
kinase A (PKA) signaling cascades [97].  MAPK activation is important for many immune 
responses, especially cytokine production. Gαi/o antagonizes Gαs’s function. Gαi/o inhibits AC, 
reducing levels of cAMP, and activating potassium channels causing membrane polarization, 
which furthers the inflammatory response [98].  Gαq/11 couples to phospholipase C (PLC) which 
hydrolyzes phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol 1,4,5-
trisphosphate (IP3) and  diacyl glycerol (DAG) [99].  The cleavage of PIP2 leads to a calcium flux 
in the  cytoplasm and activation of protein kinase C (PKC).  PKC is important for β2 integrin 
upregulation on neutrophils and eosinophils [100, 101].  Lastly Gα12/13 activates Rho guanine 
nucleotide exchange factors important for GTPase activation [99].  GTPases hydrolyze GTP and 
shut down signaling.  Signaling through specific Gα subunits creates signaling patterns often 
unique to different cell types and specific for chemokine subsets [102].  Although Gβγ subunits 
regulate different pathways than Gα signals, Gβγ pathways ultimately lead to PLC activation 
[103, 104].  The βγ subunits activate serine/threonine kinase (Akt) through phosphatidylinositol 
3- kinase (PI3K).  Akt activation induces chemotaxis, cell cycle progression and apoptosis [105, 
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106].  The multiple G protein subtypes and combinations contribute to refined chemokine 
signaling responses.  
 Inhibition of GPCRs can be mediated by the enzyme CD26/dipetidylpeptidase IV (DPP-
IV), which truncates the NH2-termini of several chemokine receptors [107].  Other synthetic 
antagonists of GPCRs are small molecules that block chemokine-binding pockets on the NH2-
terminus of the GPCR [108].  Currently the chemokine receptor antagonists for CCR1, CCR2, 
CCR5,  and CXCR3 are used to treat retroviral and auto-inflammatory diseases [109].  Other 
antagonists of GPCRs target GPCR kinases (GRKs) and β-arrestins [110].  GRKs halt GPCR 
signaling by phosphorylating serine and threonine residues at the C-terminus of the GPCRs.  β-
arrestins bind the C-terminal phosphorylated serine and threonine residues to induce GPCR 
conformational changes that no longer permit G protein binding [111].  This antagonist pathway 
also induces GPCR internalization through endosomal compartmentalization [112, 113].  This 
mechanism inactivates the GPCRs and recycles the receptor.  Interestingly β-arrestins have been 
shown to act as adaptors in MAPK, SRC, nuclear factor-κB and phosphoinositide 3-kinase 
signaling [111, 114, 115].  Chemokine signaling can be mediated through many adaptors and 
pathways in addition to the ones listed above.  This variability allows for diverse outcomes upon 
chemokine binding and subsequent signaling. 
Cytomegalovirus encoded cytokine, chemokine and chemokine/cytokine receptor homologs 
Human cytomegalovirus (HCMV) is a ubiquitous β-herpesvirus with an adult seroprevalence 
over 90% in many countries [116, 117].  HCMV primary infection is characterized by a systemic 
and productive viral replication in the human host [118].  HCMV enters latency in myeloid and 
bone marrow cells of immune competent hosts [117].  During latency viral replication is 
undetectable.  Primary infection or reactivation from latency causes morbidity and mortality in 
newborns infected in utero and immune compromised individuals like organ transplant recipients 
and AIDS patients [117, 119-123].  The ability of HCMV to survive for the life of the host 
suggests that the virus encodes proteins that evade host immune responses during all phases of 
infection [124].  Within the HCMV genome, there are 88 genes that encode proteins that are non-
essential for replication in vitro [125].  These genes may play a role in replication and 
persistence within the host (in vivo). At least 11 of these 88 genes encode chemokines [126], 
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cytokines [127, 128], and chemokine receptor [129, 130] homologs, including the UL21.5, 
US27, US28, UL33, UL78, UL111A, UL111A, UL128, UL144, UL 146, and UL147 genes, 
which are cytokine, chemokine, or chemokine/cytokine receptor homologs [124].  Virally 
encoded immune modulating proteins have also been extensively characterized in murine 
cytomegalovirus (MCMV).  These viral proteins have diverse and unique functions compared to 
their host homologs. 
Cytokine homologs in CMV 
The HCMV gene UL111A encodes a human IL-10 (hIL-10) homolog, cmvIL-10 [127, 128]. 
During latent infection alternative splicing events result in the expression of another cmvIL-10 
known as LAcmvIL-10 [131].  UL111A encodes a 175 amino acid protein during primary 
infection, while latent infection results in the truncated LAcmvIL-10 that is 139 amino acids 
long.  LAcmvIL-10 is identical to cmvIL-10 for the amino terminal 127 amino acids but differs 
in the last 12 residues [131].  Although both LAcmvIL-10 and cmvIL-10 only share a 27% 
amino acid identity with hIL-10, they are capable of signaling through the hIL-10 receptor [127, 
128, 132].  The use of recombinant proteins or deletion viruses, cmvIL-10 demonstrates 
inhibition of the production of pro-inflammatory cytokines, TNF-α, IL-1β and IL-6 from 
peripheral blood mononuclear cells and monocytes much like its human counterpart, hIL-10 
[133-135].  Similarly hIL-10 and cmvIL-10 share the ability to decrease the expression of major 
histocompatibility complexes (MHC I and MHC II) on monocytes.   Furthermore, cmvIL-10 
inhibits the maturation of monocyte-derived dendritic cells (DCs) [136-138] and plasmacytoid 
DCs [139] and their subsequent effector functions.  cmvIL-10 dampens microglial macrophage 
functions, which aid in the chemotaxis of activated T lymphocytes [140].  In these cases the 
cmvIL10 functions to dampen the immune responses. Besides immune modulation of myeloid 
cells, cmvIL10 contributes to the proliferation and differentiation of B lymphocytes [141] and 
monocytes [142] but not cytotoxic T lymphocytes.  CMVs with a UL111A deletion does not alter 
their replication but causes a shift in the differentiation of monocytes to DCs rather than 
phagocytic macrophages [143].  It is not clear the role LAcmvIL10 plays in this scenario. 
MCMV shares many homologous genes with HCMV, but MCMV does not encode a direct 
homolog of hIL-10.  MCMV exploits IL-10 during salivary gland infection for its survival in 
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vivo via CD4+ T lymphocytes immune regulation [144]. Perhaps this points to the alteration of 
pro-inflammatory responses that may allow HCMV to productively replicate during primary 
infection and persist within the host during latency. 
Cytokine receptor homologs in CMV 
HCMV UL144 encodes a type I transmembrane glycoprotein which was originally identified as a 
homolog of tumor necrosis factor receptor (TNFR) superfamily members [145].  In spite of this 
homology the UL144 protein (pUL144) does not function by binding TNF ligands [145, 146].  
The pUL144 extracellular domain, binds to B- and T- lymphocyte attenuator (BTLA) [147, 148].  
BTLA is an inhibitory receptor found on T lymphocytes that inhibits CD4+ T lymphocyte 
activation [147].  HCMV may utilize BTLA binding to alter CD4+ T lymphocyte responses in 
vivo.  pUL144 also induces NF-κB activation and modulation of host gene expression through 
interactions with the TNFR associated factor 6 (TRAF6) and tripartite motif 23 protein 
(TRIM23) [146, 149].  Through this pathway, pUL144 induces expression of CCL22 [146, 150], 
which attracts regulatory T lymphocytes [151], and could dampen T-lymphocyte detection of 
CMV in vivo. 
CXC chemokine homologs in CMV 
Within the HCMV genome, there are two ORFs, UL146 and UL147 that encode CXC chemokine 
homologs [152].  UL146 encodes viral CXCL-1 (vCXCL-1) and UL147 encodes viral CXCL-2 
(vCXCL-2).  MCMV does not encode a CXC chemokine homolog but does have a CC homolog 
[153].  The amino acid makeup of vCXCL-1 varies among different HCMV strains [154].  
Sequencing studies show that UL146 is one of the most variable genes in the HCMV genome 
[155-163]. This variability could contribute to CMV pathogenesis [158, 160, 164].  For instance, 
the attenuated lab adapted strain, AD169, is missing these ORFs within the 15kb UL/b’ region, 
but the virulent Toledo strain still maintains this region [126].  The absence of UL146 and 
UL147 from AD169 does not affect viral replication in vitro, thus the two gene products are 
hypothesized to play a role in survival in vivo [126, 155, 156].  Deletion of UL146 from the 
Toledo strain limited HCMV’s ability to infect fibroblasts and promote neutrophil chemotaxis 
[152]. Of the two viral CXC chemokine homologs, vCXCL1 has been extensively characterized. 
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It mediates chemotaxis through binding of CXCR2 and sometimes CXCR1 [152, 165].  
Furthermore, vCXCL1 is capable of inducing calcium flux in isolated human neutrophils similar 
to CXCL8 [152, 166].  Different clinical isolates with variations in UL146 show different 
binding affinities for CXCR2 which may contribute to differences in neutrophil activation. 
CC chemokine homologs in CMV 
HCMV encodes the UL128 protein (pUL128), which forms part of a pentameric complex with 
glycoprotein H (gH; UL115), glycoprotein L (gL; UL75), pUL130, and pUL131A.  This 
complex plays an important role in mediating HCMV entry into endothelial, epithelial cells, DCs 
and leukocytes [409, 423, 424].  Expression of the pentameric complex varies depending upon 
which cell type the virus was propagated [167-170].  In addition to its role in entry, pUL128 
shows limited homology to CC chemokines [419].  pUL128 has two cysteines near the N-
terminus, which is characteristic of the C-C motif found in human C-C chemokines [171].  This 
putative chemokine promotes chemotaxis of PBMCs similar to the human-encoded CCL3 (MIP-
1α) [172].  pUL128 induces expression of the pro-inflammatory cytokines, TNF-α and IL-6, 
which may aid in the recruitment of cells important for dissemination or clearance of the virus 
[173].  The UL128 gene does not encode a functional protein in clinical strains (Toledo and 
Merlin) due to a frameshift and partial inversion mutation [171].  This mutation likely 
contributes to survival of these strains in vivo by evading the host immune response because 
pUL128 induces expression of pro-inflammatory cytokines that may dampen viral infection.  
MCMV encodes a CC chemokine, which is expressed as a result of splicing of m131 and m129 
genes in MCMV to produce MCK2 [174, 175]. Deletion of MCK2 results in defective viral 
dissemination to the salivary gland and less inflammation at the site of inoculation [176, 177].  
MCK2 recruits myeloid progenitor cells [178, 179] and monocytes [180], which are involved in 
viral dissemination to the salivary gland.  Therefore, it appears that MCK2 is involved in the 
recruitment of cells important for dissemination and these cell types can serve as a reservoir for 
latent infection [181-184].   Recent studies have shown that MCK-2 and gH/gL form a complex 
that promotes MCMV infection of monocytes and macrophages in vitro and in vivo [185] 
suggesting that MCK2 and HCMV pUL128 may function by promoting entry into specific cell 
types that determine CMV tropism. 
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Chemokine receptor homologs in CMV 
There are four genes encoding chemokine receptor homologs in the HCMV genome: US27, 
US28, UL33, and UL78 [129, 130].  Of these chemokine receptor homologs US28 is the most 
extensively characterized.  The US28 protein (pUS28) is a potential oncogene and an immune 
modulator during HCMV infection [186-188].  pUS28 shows 30% amino acid identity with 
CCR1with some similarity to both CCR2 and CCR5 [189]. pUS28 is the only viral chemokine 
receptor that binds both CC and CX3C chemokines [189-191].  Infected cells expressing pUS28 
signal through this virally encoded chemokine receptor to induce cellular responses similar to 
host CC chemokine receptors [189, 192-195].  Ligand binding to pUS28 induces cellular 
responses including MAPK activation, calcium flux, cellular migration and activation of 
transcription factors like the cAMP responsive element binding protein (CREB) and NF-κB 
[192-196].  In an independent, constitutive signaling pathway, pUS28 induces phospholipase C 
activation which leads to the production of secondary messengers, IP3, DAG and NF-κB 
activation [197-200].  Through these signaling pathways, it is proposed HCMV induces smooth 
muscle cell migration which accelerates atherosclerosis [193, 201].  pUS28 has been suggested 
to be an immunoevasin protein based on its ability to bind and internalize chemokines, which 
limits their chemotactic effects on surrounding cells [192, 202].  Furthermore, pUS28 inhibits 
CCL2 and CCL5 mediated chemotaxis of monocytes [204].  Cells infected with HCMV 
expressing pUS28 can bind a variety of host chemokines including CCL2, CCL7, CCL4 and 
CCL5 leading to a reduction in the host immune response in virally infected tissues [203].  
HCMV has been implicated in human cancer, especially glioblastomas [205-208]. Whether this 
is causation or coincidence remains to be tested.  In support of pUS28 being involved in 
transformation, NIH-3T3 murine fibroblasts expressing pUS28 experience increased growth, 
enhanced cell cycle progression, and vascular endothelial growth factor (VEGF) production 
[206]. Injection of these cells into nude mice resulted in rapid tumor formation [206, 207].  
Transgenic mice overexpressing pUS28 leads to intestinal neoplasia that was linked to the 
dysregulation of cellular proliferation genes like survivin and cyclin-D1 and co-expression of 
CCL2 [209].   The increased proliferation in cells expressing pUS28 is related to NF-κB 
mediated upregulation of STAT/IL-6 [208].  MCMV encodes a chemokine receptor homolog, 
M33. When M33 is deleted, it limits dissemination, salivary gland replication and is associated 
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with reduced reactivation from spleen and lung explants [210, 211].  Studies that replace MCMV 
M33 with HCMV US28 showed partial complementation emphasizing the similar functions that 
these proteins have in their respective viruses and hosts [210]. 
 US27 is expressed as an HCMV late gene.  Currently, US27 has not been shown to have 
constitutive signaling activity, nor does it bind any ligand [212].  The US27 protein, pUS27, can 
be detected intracellularly in multivesicular bodies and also on the cell surface.  Mutant viruses 
that do not encode US27 have impaired extracellular spread in endothelial cells and fibroblasts 
[213].  However, US27 deletion does not affect cell to cell spread.  Although pUS27 does not 
trigger constitutive signaling, its heterodimerization with pUS28 allows the pair to constitutively 
signal [214].  
 The HCMV encoded UL33 gene is conserved across all CMV species including MCMV 
(M33). The UL33 and M33 proteins show constitutive signaling [199, 200, 215, 216], but they 
do not play a role in viral replication in vitro or viral dissemination in vivo [217].  pUL33 can 
form a complex with pUS28, but it does not alter pUS28’s ability to signal through 
phospholipase C.  It does, however, alter NF-κB induction [214].  Therefore, pUL33 may also 
play an immune modulatory role along with pUL128.  
 Like UL33, UL78 is conserved among all β-herpesviruses, suggesting that both play a 
role in vivo because they are not required for replication in vitro [218].  pUL78 like the other 
previously described receptor homologs can complex with pUS28 [214, 219].  This complex 
formation does not alter pUS28 signaling.  Furthermore, UL33 and UL78 can heterodimerize 
with host CCR5 and CXCR4 in THP-1 cells [220].  Because pUL33 and pUL78 can dimerize 
with CCR5 and CXCR4, these viral proteins can alter responses to their ligands, CCL5 and 
CXCL12 [220].  It appears that virally encoded chemokine receptors may skew the immune 
response to HCMV infection in vivo as well as promote viral pathogenesis. 
 The UL21.5 gene encodes the protein, pUL21.5, which is a secreted glycoprotein that is 
not vital for HCMV growth in fibroblasts [221]. pUL21.5 can bind CCL5 but not CCL2, CCL3 
or CXCL-8, suggesting that the role of pUL21.5 is to sequester CCL5 [189, 205]. The mRNA for 
pUL21.5 is incorporated into the HCMV virion presumably so that it can be translated 
immediately upon virus entry [222].  Viruses without this gene may not fare well in vivo where 
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infection of cell types other than fibroblasts is required for productive and continued replication. 
Without sequestering CCL5 CMV would not be able to evade the host immune response. 
 
CMV entry 
All herpesviruses encode the glycoprotein complex consisting of glycoproteins H and L (gH/gL) 
and B (gB), which are essential for herpesvirus entry into host cells [223-225]. HCMV 
glycoproteins, gH/gL will not fuse with host cell membranes unless gB is present [226, 227]. 
Therefore HCMV virions that lack gB are able to assemble but not enter host cells [228]. 
Coincidentally gL deletions also inhibit viral entry [229].  The gH/gL complex can recognize and 
bind receptors for entry into host cells independently or by forming a complex with other 
glycoproteins [225]. 
 CMV glycoprotein B 
Together gB and glycoproteins M and N (gM/gN) mediate the initial adsorption of HCMV onto 
heparan sulfate glycosaminoglycans (GAGs) [230].  Cell-cell fusion is mediated through gB and 
gH/gL in epithelial, endothelial cells, and fibroblasts [170, 231]. This fusion event occurs only if 
both gB and gH/gL are present. While glycoprotein O (gO) and pUL128-131 form complexes 
with gH/gL, their expression does not increase fusion efficacy in any cell type [170].  A 
relatively small amount of gH/gL reach the membrane without forming a complex with gO or 
pUL128-131. This suggests that gB and gH/gL are collectively involved in cell-cell fusion 
events.  Recent studies have indicated that gB acts downstream of gH/gL binding [231]. This 
demonstrated by trans- expression of HCMV gB on epithelial cells, which can initiate fusion 
events with other cells expressing gH/gL [232].  MCMV encodes a glycoprotein B that is 
functionally homologous to HCMV gB [233].  
CMV gH/gO/gL trimeric complex 
HCMV entry into fibroblasts is predominantly mediated by gH/gL assembled with glycoprotein 
O (gO) through a disulfide linkage [170, 234].  Extracellular CMV uses the trimeric gH/gL/gO 
complex to enter fibroblasts by fusion at the plasma membrane [235].  Previous studies have 
indicated that in the clinical strain ‘TR’, gH/gL does not form a complex with gO at the viral 
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envelope [236].  Instead gO is responsible for chaperoning gH/gL from the rough endoplasmic 
reticulum to the Golgi apparatus and trans Golgi network [232, 237].  While the lab adapted 
strain AD169 trafficked gO to and from the trans Golgi network to be incorporated in the viral 
envelope with gH/gL [238].  The differences in the function of gO between these two strains 
indicates that the lab adapted strain is more suitable for fibroblast entry while the clinical strains 
may preferentially use a different complex.  An HCMV gO-null mutant is highly impaired in 
entry into fibroblasts, endothelial, and epithelial cells [232, 239-242].  Furthermore the TR gO-
null mutant was unable to enter those cells even when normal virion particles were produced 
[232].  Previous studies have shown that gO-null mutants are not impaired in cell-associated 
focal virus spread in cell culture [243].  This indicates that the gH/gL/gO complex is important 
for extracellular CMV fusion into these different cells but not cell-to-cell spread.  The gH/gL/gO 
complex of MCMV is functionally homologous to the HCMV gH/gL/gO complex in vitro [244].  
Although the CMV gH/gL/gO complex is important for initial entry and infection of salivary 
gland tissue, it is not vital for cell-to-cell spread [245]. This cell to cell spread is important for 
infection in vivo. 
CMV gH/gL/pUL128, 130, 131A pentameric complex 
The gH/gL/pUL128, 130, 131A pentameric complex was first discovered in strains AD169 and 
Towne, which had been passaged several times in fibroblasts and lost the ability to infect 
epithelial and endothelial cells [126].  Subsequent sequencing of AD169 and Towne revealed 
that 22 genes within the HCMV genome were mutated.  These mutations spanned from UL128 to 
UL151.  By repairing mutations only in the UL128, UL130 and UL131A genes, infection of 
epithelial and endothelial cells was restored in the lab propagated strains [168, 246].  Subsequent 
characterization of the gH/gL/pUL128, 130, 131A complex revealed that it is found in the 
HCMV envelope and mediates infection of endothelial, epithelial, monocytic and dendritic cells 
[169, 244, 247-249].  This entry into epithelial and endothelial cells is via pH-dependent 
endocytosis and cell-to-cell spread [250].  The complex will not traffic to the envelope and serve 
its function in entry if any of the five proteins are missing [251].  Expression of the HCMV 
pentameric or trimeric complex (gH/gL/gO), affects its preferred entry mechanisms, which vary 
depending on the cell types in which they are propagated [167].  For instance endothelial cells 
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only release virus progeny that express low amounts of the gH/gL/pUL128, 130, 131A 
pentameric complex.  Also progeny propagated in epithelial cells preferentially enter epithelial 
cells by fusion at the plasma membrane while HCMV propagated in fibroblasts enter epithelial 
cells through pH-dependent endocytosis [252].  As mentioned previously pUL128 shows limited 
homology to CC chemokines [171]. Thus far pUL128 has been characterized for both its 
chemokine and entry capabilities.  In a parallel fashion, gH/gL from MCMV forms a complex 
with the gene products of the m131-129 ORFs [185].  The MCMV m131-129 ORFs encode 
MCK-2, a C-C chemokine homolog [174, 175].  The gH/gL/MCK2 trimeric complex mediates 
infection of macrophages in vitro and in vivo and enhances infection of epithelial cells in vitro 
[185].  These same characteristics are also attributed to the HCMV gH/gL/pUL128, 130, 131A 
pentameric complex, implying MCK2 functions as an entry protein besides being important for 
dissemination to the salivary gland [176, 177].  This information suggests that HCMV pUL128 
and MCMV MCK-2 plays dual roles as chemokines and as part of a glycoprotein complex used 
for entry into specific cells. 
CMV entry pathways and cellular receptors 
Entry of both lab adapted strains (AD169) and clinical isolates (TR) into fibroblasts is mediated 
by fusion at the plasma membrane, and not by pH dependent endosomal entry [235, 250]. TR 
entry into epithelial and endothelial requires endosomes and the gH/gL/pUL128, 130, 131A 
pentameric complex [250].  This mechanism of entry is dependent upon the low pH in acidified 
endosomes.  There are several cellular receptors that are involved in mediating HCMV entry: 
heparan sulfate proteoglycans (HSPGs), α/β-integrins, epidermal growth factor (EGFR), and 
platelet derived growth factor receptor-α [238].  When HS GAGs are bound to a protein core 
they are called heparan sulfate proteoglycans (HSPGs) [253-255].  The HS backbone is 
generated by alternating glucuronic acid (or iduronic acid) and N-acetylglucosamine.  The HS 
chains are modified by adding sulfate groups at various positions [256-259].  HS chains are 
highly negatively charged and highly complex due to enzymatic modifications [260, 261].  
HSPGs bind to cell adhesion molecules, growth factors, chemokines, and factors involved in 
angiogenesis and blood coagulation [262-265].  HSPGs have also been implicated in herpesviral, 
malarial and amyloid-related pathogenesis [230, 266-270].  HCMV gB and gM/gN bind to HS 
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on the cell surface [230]. This is the important first step in a multistep fusion event.  CMV uses 
many receptors in order to facilitate fusion. 
 EGFR is expressed on fibroblasts and monocytes [243, 271, 272].  Each cell type is 
capable of HCMV infection. HCMV infection activates EGFR-dependent signaling which is 
important for initiating infection [271].  However HCMV triggered EGFR activation does not 
occur in fibroblasts, and blockade of EGFR-cytoplasmic signaling does not inhibit HCMV entry 
in these cells. These data leave the question open as to whether there is a correlation between 
EGFR expression and HCVM infection [273], suggesting there are other mechanisms for 
initiating infection. HCMV gB binds integrins: α2β1, α6β1, and αVβ3 integrins [274] and 
induces integrin signaling [275].  Peptides that mimic the gB disintigrin binding motif blocks 
HCMV and MCMV entry, pointing to the importance of integrins in virus entry [274].  Another 
growth factor receptor, PDGFRα, is induced by HCMV infection of fibroblasts [276]. Inhibition 
of PDGFRα signaling either by blocking receptor binding or the signaling pathway itself inhibits 
HCMV immediate early gene expression [276]. These results illustrate that several viral 
glycoprotein interactions with cell surface receptors are necessary to mediate HCMV entry. 
Disruption of these interactions hinders CMV entry and could point to potential targets for novel 
drugs that inhibit CMV entry. 
CMV cell-to-cell spread 
In addition to the attachment/fusion pathways described above, HCMV also infects cells through 
cell-to-cell spread.  Anti-gB antibodies neutralize initial and extracellular virus entry into all cell 
types while anti-gH/gL/pUL128, 130, 131A pentameric complex antibodies only prevent entry 
into epithelial cells [277].  However anti-gB antibodies do not prevent CMV cell-to-cell spread 
meaning that gB is only involved in initial viral entry [213, 278, 279].  Deletion or modification 
of the gH/gL/pUL128, 130, 131A pentameric complex inhibits initial entry into epithelial cells 
and cell-to-cell spread of HCMV in epithelial cells [250].  Furthermore lab adapted strains 
appear to use both the extracellular fusion mechanisms described above and cell-to-cell spread 
while clinically isolated HCMV preferentially use cell-to-cell spread [280].  The gH/gL/pUL128, 
130,131A appears to mediate cell-to-cell spread in epithelial cells which is useful in vivo where 
CMV encounters diverse cell types including epithelial cells. 
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Treatment of HCMV 
HCMV vaccine development 
While several vaccines are currently in human clinical trials [281], there are no currently 
approved vaccines for HCMV.  An HCMV strain, Towne, was tested as a vaccine in renal 
transplant recipients [282].  Although Towne failed to prevent infection after disease, it reduced 
the severity of end organ disease (EOD).  Subsequently live virus vaccines using a Towne 
background or an attenuated strain of Toledo have been tested in phase 1 clinical trials [283-
285].  A proposed subunit vaccine using gB has reached phase 2 clinical trials [286, 287]. The 
results from this study show that the gB subunit vaccine protected ~50% of seronegative female 
patients from primary HCMV infection or reduced viral load in the kidney and liver of infected 
transplant patients [286, 287].  Another subunit vaccine containing both gB and the tegument 
protein pp65 reduced CMV reactivation in bone marrow transplant recipients [288, 289] Yet 
another proposed vaccine contains gB, pp65, and the major immediate-early proteins (MIEPs) 
[290].  This vaccine has yet to reach human trials.  Another approach is the use of antibodies 
against gB or the HCMV pentameric complex, gH/gL/pUL128-131, to reduce HCMV infection 
in epithelial and endothelial cells [291, 292].  Recently, CD8+ T lymphocyte CMV peptides 
composed of multiple ORFs have been identified and are currently being tested [196]. So far 
over one hundred HCMV ORFs were shown to be immunogenic for CD4(+) and/or CD8(+) T 
cells.  A vaccine was tested in rhesus macaques, which induces broadly neutralizing antibodies 
induced following overexpression of Rhesus CMV UL128 pentameric complex (RhCMV 
UL128C) [197].  Rhesus CMV (rhCMV) pUL128 is homologous to HCMV gH/gL/pUL128, 
130, 131A pentameric complex.  The RhCMV pUL128C is also important for entry into 
epithelial and endothelial cells. Administration of this complex inhibits entry of RhCMV into 
epithelial, endothelial and fibroblasts.  However when the RhCMV gB is expressed it produces a 
substantially lower amount of neutralizing antibodies. These data suggest that the immune 
modulatory proteins like pUL128, can be exploited during vaccine development [197]. The 
development of vaccines against HCMV has been unsuccessful in part due to HCMV’s ability to 
modulate and evade the host immune system [124, 292]. Superinfection of rhesus CMV in vivo 
requires evasion of CD8+ T lymphocyte immunity by the viral encoded inhibitors of major 
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histocompatibility complex class I (MHC-I) antigen presentation [293]. RhCMV glycoproteins 
(US2-11) promote immune evasion of CD8+ T lymphocytes in vivo. This process is one that 
complicates the development of preventive CMV vaccines. One characteristic of CMV is its 
ability to persist within the host even when faced with a strong immune response. For instance, 
in immune competent individuals up to 10% of their specific CD4+ and CD8+ T lymphocytes 
are specific for CMV but cannot prevent HCMV infection [124, 196].  Clearly the effects of the 
HCMV immune modulatory factors must be circumvented in order to develop a successful 
vaccine. 
 
HCMV antivirals 
Due to the lack of an HCMV vaccine, treatment of HCMV relies on antiviral therapeutics. 
Current anti-HCMV therapeutics include: ganciclovir (GCV), valganciclovir (oral prodrug of 
GCV; VGCV), foscarnet (FOS) and cidofavir (CDV) [294].  Current anti-HCMV therapeutics 
target the viral DNA chain elongation through the use of a nucleoside analogs, which mimic 
actual nucleotides. The nucleoside analog serves as a poor substrate for chain elongation because 
it lacks a hydroxyl group for addition of the next nucleotide [295, 296].  HCMV expressed 
kinase is necessary to activate GCV [295-299]. Therefore nucleoside analogs such as GCV, 
disrupt viral DNA synthesis. GCV has been used to treat congenital infections and HCMV 
disease in transplant recipients and AIDS patients [294].  Unfortunately the current anti-HCMV 
therapeutics, FOS and CDV are nephrotoxic [295].  Furthermore long-term use of anti-HCMV 
therapeutics has contributed to the evolution of HCMV resistance to these drugs. For organ 
transplant recipients prophylaxis or preemptive therapy is used for 100 to 200 days 
posttransplant [300].  This extended anti-HCMV treatment contributes to a 5%-10% chance of 
developing GCV resistant strains among transplant recipients and AIDS patients [294].  For 
example, it is estimated that up to 27.5% of circulating HCMVs are GCV resistant (GCV
R
) [301, 
302].  Mutations in the HCMV UL54 DNA polymerase and UL97 phosphotransferase gene 
confer resistance to GCV [119, 120, 303, 304]. Mutations in the HCMV UL54 DNA polymerase 
gene confer resistance to GCV, CDV, and FOS [119, 294].  Development of novel anti-CMV 
therapeutics needs to address both the toxicity and development of antiviral resistance.  
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Summary and Research Aims 
HCMV increases morbidity and mortality in congenitally infected newborns and 
immunocompromised individuals.  There is an urgent need for a vaccine or effective therapeutic. 
Faced with the difficulties of vaccine development an effective therapeutic is an approach to 
minimize CMV pathology.  Current HCMV therapeutics target viral DNA replication. 
Resistance to these antivirals is emerging. Therefore it may be beneficial to target other aspects 
of the virus life cycle.  For instance, if a therapeutic drug inhibited HCMV entry it would 
alleviate the need for prolonged use of the current antivirals. Furthermore understanding of CMV 
pathogenesis may aid in developing effective vaccines that can counteract important HCMV 
encoded immune modulators.  CMV encoded chemokines that aid in viral infection, 
dissemination, and the antiviral immune response.  These chemokines are hyper variable which 
could factor into viral pathogenesis.  
 
We begin to understand the CMV lifecycle and pathogenesis by testing HS binding peptides that 
affect entry, examine the role of viral chemokines on dissemination by using murine CMV viral 
recombinants that overexpress CXC chemokines and dissect the function of CXCL-1s using 
recombinant vCXCL-1 proteins. The following three hypotheses were tested and detailed in this 
thesis: 
 
1. Heparan sulfate binding D-peptides reduce CMV infection in vitro and in vivo. 
2. vCXCL-1 contributes to CMV viral dissemination. 
3. Polymorphisms in vCXCL-1, lead to differences in neutrophil activation that contribute to 
HCMV pathogenesis. 
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CHAPTER I 
THE D FORM OF A NOVEL HEPARAN SULFATE BINDING PEPTIDES DECREASES 
CYTOMEGALOVIRUS INFECTION IN VIVO AND IN VITRO  
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Abstract 
Human cytomegalovirus (HCMV) infection in utero can lead to congenital sensory neural 
hearing loss and mental retardation. Reactivation or primary infection can increase the morbidity 
and mortality in immune suppressed transplant recipients and AIDS patients. The current 
standard of care for HCMV disease is nucleoside analogs, which can be nephrotoxic.  In addition 
resistance to current treatments is becoming increasingly common.  In an effort to develop novel 
CMV treatments, we tested the effectiveness of the D-form of a novel heparan sulfate binding 
peptide, p5RD, at reducing infection of ganciclovir (GCV) resistant HCMVs in vitro and MCMV 
in vivo.  HCMV infection was reduced by greater than 90% when cells were pretreated with 
p5RD.  Because p5RD acts by a mechanism unrelated to those used by current antivirals, it was 
effective at reducing GCV resistant HCMVs by 85%. We show that p5RD is resistant to common 
proteases and serum inactivation, which likely contributed to its ability to significantly reduced 
infection of peritoneal exudate cells and viral loads in the spleen and the lungs in vivo.  The 
ability of p5RD to reduce HCMV infectivity in vitro including GCV resistant HCMVs and 
MCMV infection in vivo suggests that this peptide could be a novel anti-CMV therapeutic. 
  
Introduction 
Human cytomegalovirus (HCMV) infection or reactivation from latency causes severe 
disease in immune-suppressed transplant recipients, AIDS patients, and newborns [1].  Infection 
can lead to mononucleosis-like symptoms, interstitial pneumonia, gastroenteritis, retinitis, or 
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organ transplant rejection [2-6].  In utero infection can lead to microcephaly, 
hepatosplenomegaly and sensorineural hearing loss (SNHL) in newborns [7, 8].  
 Due to the limited success of HCMV vaccines [9, 10], HCMV treatment consists 
of antiviral drugs like ganciclovir (GCV), valganciclovir (i.e., an oral prodrug of GCV), 
cidofovir (CDV), and foscarnet (FOS). These antivirals are nucleoside analogs that target viral 
DNA synthesis [11]. Not only are FOS and CDV nephrotoxic [12], but long-term use of 
antivirals has contributed to the evolution of HCMV resistance [13, 14]. One approach to 
develop novel anti-CMV therapeutics is to target other aspects of the HCMV lifecycle other than 
viral DNA synthesis. 
 A potential target for anti-CMV therapeutics is the initial, critical attachment step 
during viral entry in which HCMV binds to cell surface heparan sulfate (HS) [15, 16].  HS 
consists of glucosamine and glucuronic acid or iduronic acid moieties that are N-acetylated as 
well as N- or O-sulfated, which allows for incredible diversity in the structures on different cell 
types [17-19].  Heparan sulfate proteoglycans (HSPGs) participate in physiological processes 
including embryonic development, binding of growth factors, chemokine transcytosis, cell 
adhesion and lipid metabolism [20].  CMVs utilize HSGPs for their initial attachment to the cell 
and subsequent initiation of infection [15]. Previous studies have shown that HCMV may 
preferentially bind to 6-O-sulfated or 3-O-sulfated heparan sulfate moieties during viral entry 
[21, 22].  The distribution of HS on host cells in addition to viral preference for specific subtypes 
of HS, make this structure a potential anti-CMV therapeutic target.   
One approach to limit HS-mediated viral entry is through the use of peptides designed to 
preferentially bind HSPGs.  Peptides offer several benefits as therapeutics. They can be readily 
synthesized, designed to be highly specific, easily modified to enhance biological activity, and 
less toxic because they are catabolized into amino acids [23].  However, their susceptibility to 
proteases and short serum half-life have historically limited the use of peptides as therapeutics 
[24].  Recently several HS-binding peptides have been tested in vitro and in vivo for their ability 
to inhibit herpesvirus infections. The HS reactive peptide, G2, a 10-mer derived from a phage 
display library, inhibits HSV-1 infection in vivo [25].  Additionally, a peptide known to bind to 
hypersulfated HS, p5+14, was shown to effectively inhibit HS-mediated entry of both murine 
and human CMV as well as HSV in vitro [26].  In this his current study we characterize a related 
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peptide, p5R, which is 14 amino acids shorter and has a higher propensity to form an α-helix.  
Furthermore, we hypothesized that D- form of peptide p5R, p5RD, would still inhibit CMV 
infection in vitro and would be more efficacious in vivo due to its resistance to proteolytic 
cleavage. Finally, we tested whether p5RD inhibited GCV-resistant HCMVs in vitro in an effort 
to show its efficacy against clinical strains of HCMV. 
Materials and Methods 
Peptide synthesis 
Using p5 as a template to design p5R and p5RD the lysine resides were replaced with arginine 
residues to yield p5R - GGGYS RAQRA QARQA RQAQR ARGAR Q. Both peptides have a 
positive net charge of +8 and a predicted alpha helical secondary structure according to 
ITASSER predictions [27, 28].  Peptides p5R and p5RD were purchased from Anaspec (Fremont, 
CA) and purified as previously described [26]. 
Cells and mice 
All cells used in our experiments were low passage-number (less than 22 passages). Human 
normal lung fibroblasts (MRC-5) were cultured in MEM (Corning, Manassas, VA and HyClone, 
Logan, UT) supplemented with 10% Fetal Bovine Serum – Premium (FBS; Atlanta Biologicals, 
Atlanta, GA), and 2mM L-glutamine (HyClone, Logan, UT). Human foreskin fibroblasts (HFF; 
ATCC) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, HyClone, Logan UT) 
with 2mM sodium pyruvate (Corning, Manassas, VA and HyClone, Logan, UT) supplemented 
with 10% FBS, and  2mM L-glutamine. Human aortic endothelial cells were cultured in EGM-2 
Bullet Kit (Lonza, Walkersville, MD) supplemented with 6% FBS, and 2mM L-glutamine. 
Human pigment epithelial cells (ARPE-19) were cultured in DMEM:F12 medium (Corning, 
Manassas, VA and HyClone, Logan, UT) supplemented with 10% FBS. Mouse embryonic 
fibroblasts 10.1 (MEF 10.1) were cultured in DMEM (Lonza, Rockland, ME) supplemented with 
10% Fetal Clone III serum (FCIII) (Hyclone, Logan, UT), 100U/ml Penicillin/Streptomycin and 
2mM L-glutamine. All cells were grown at 37°C and 5.0% CO2.  Male and female BALB/c mice 
were purchased from Jackson Laboratory (Bar Harbor, ME) and bred in the University of 
Tennessee Laboratory Animal Facility.  Eight to 12 week old mice were used in all experiments.  
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All mice were housed under specific pathogen-free conditions and the experiments were 
performed under the auspices of University of Tennessee IACUC-approved protocols.  
Viruses 
HCMV TB40E expressing luciferase under the control of the UL18 promoter was a gift from 
Drs. Christine O’Connor and Eain Murphy (University of Buffalo and FORGE Life Science, 
LLC). Virus was cultured on HFF cells and titered using plaque assay or luciferase/luminescent 
expression assay using a Synergy 2 plate reader (BioTek, Winooski, VT).  Based on a standard 
curve, approximately fifteen plaques are equivalent to 1000 relative light units (RLU).  
 Recombinant, Wild Type and GCV resistant HCMVs (T3261, T3252, T3265 and T3429) 
were generated as described [29-32]. These recombinant viruses were a kind gift from Dr. 
Sunwen Chou (Oregon Health Sciences University).  Recombinant viruses were titered using 
plaque assays and secreted alkaline phosphatase (SEAP) assay[29].  HCMV clinical isolates, 
CH19 and CH-13 [14], were a kind gift from Dr. Nell S. Lurain (Rush University).  All viruses 
were titered using 0.5% agarose overlay in a plaque assay.  
 MCMV K181 [33] was cultured in vitro in MEF 10.1 cells. The viral titer was 
determined via plaque assay. All viruses were stored at -80°C until use. 
Luciferase assay 
Peptide reduction of HCMV TB40E infection was measured using a luciferase assay. Briefly, 
cells were seeded into 24-well plates. After the cells reached 80-85% confluency, peptide, 
suspended in 10% FBS/PBS was added. Control treatments included 10% FBS in PBS without 
peptide. After 30 minutes virus was added to cells at ~35-50 pfu or ~2500-3000 RLU and 
allowed to incubate at 37° C for 60 minutes. Following virus incubation, the peptide and virus 
was removed and fresh media was added. Plates were incubated at 37° C in 5% CO2 for 3 days.  
 On day 3, medium was removed and cells were washed once with PBS. Cells were lysed 
using the passive lysis buffer (Promega, Madison, WI). Cell lysate was pelleted and luciferase 
assay reagent was combined with equal amounts of supernatant into an opaque 96-well 
microplate. Luminescence was measured as RLU using a Synergy 2 plate reader (BioTek).  The 
RLU values for peptide-untreated and uninfected treatment served as a negative control and were 
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subtracted as background.  Peptide-untreated virally-infected cells served as the positive control 
and normalized to 100%. Data was analyzed using Prism 5.0 (GraphPad Software, La Jolla, CA). 
Data was expressed as percent infection (100x (number of RLU after treatment/ RLU in the PBS 
treated cells)). 
Proteolytic stability 
Proteolytic stability was measured following incubation with proteases or serum. The peptides 
were incubated with trypsin (Lonza, Walkersville, MD) or elastase (Sigma, St. Louis, MO) at 
100 μg/ml, or FBS, or human serum for 30 or 60 minutes then added to cells 30 minutes prior to 
infection with virus.  
Plaque reduction assay 
Peptides were screened for their ability to reduce infection of the BAC-derived recombinant 
GCV-resistant HCMV and clinically isolated GCV-resistant strains using a plaque reduction 
assay on MRC-5 and HFF cells. Cells were treated with peptide or PBS for 30 minutes prior to 
the addition of virus. After one hour of incubation, the mixture was removed and replaced with a 
0.5% agarose in complete MEM (MRC-5 cells) or DMEM (HFF cells) medium. The plates were 
incubated at 37°C and 5.0% CO2 for 7 to 10 days when plaques began to develop.  Plaques were 
manually counted using a dissection microscope after staining with Coomassie blue.  For 
MCMV in vivo experiments, MEF 10.1 cells were infected with serial dilutions of homogenized 
organs or infected peritoneal exudate cells (PECs).  Following a 1 hr. incubation, the media was 
removed and fresh 2% carboxymethyl cellulose (Sigma Aldrich, St. Louis, MO; CMC) in 
complete DMEM was added.  Cells were incubated at 37°C and 5.0% CO2 for 5 days then 
stained with Coomassie stain and plaques counted.  
Biodistribution of peptides 
To determine the distribution of p5RD among the relevant organs, mice were injected i.v. in the 
lateral tail vein, with I
125 
labeled peptides (< 120 µCi, 20 µg of peptide).  At 1, 2, 4 or 24 hr. 
post-injection mice were euthanized with isoflurane inhalation overdose and the spleen, liver, 
lung, and eight other tissues were harvested and the tissue radioactivity measured as previously 
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described [34]. The biodistribution of radiolabeled peptide was expressed as percent injected 
dose per gram of tissue (%ID/g). 
Data and statistical analyses 
All data were normalized to 100% using the peptide untreated and infected positive control data. 
The data are the combined from three or more independent experiments with at least three 
replicates in each experiment. Error bars represent the standard deviation (SD). Statistical 
significance was calculated using a Student’s t test, Man Whitney, or 2 way ANOVA followed 
by Bonferroni posttests.  The IC50 values were calculated using a linear regression sigmoidal 
dose dependent test. All analyses were performed using Prism 5.0 (GraphPad).  A p-values less 
than 0.05 were considered statistically significant. Significant values are labeled as *=p<0.05, 
**=p<0.01, ***=p<0.001, NS=non-significant reduction in infection.   
Results 
Peptide efficacy in vitro 
Previously we have shown that the p5-related peptides bind amyloid deposits via 
interactions with hypersulfated HS and amyloid fibrils and can acts as an inhibitor of herpesvirus 
entry [26, 34, 35].  The synthetic peptides, p5R and p5RD, are comprised of the heptad repeat 
[AQRAQAR] in the L and D-forms, respectively.  Both have an overall +8 net charge and reduce 
MCMV infection by >75% (data not shown)[26].  We also showed that the peptides do not affect 
cell viability (Supplemental Figure 1.S1).  Furthermore, the peptides have a similar IC50  for 
blocking infection of human fibroblasts with a luciferase-expressing TB40 HCMV (48.5μM p5R 
and 60.2μM p5RD).  At a concentration >200 μM, both p5R and p5RD reduce HCMV infection 
by ≥90% (Figure 1.1A).  
HCMV infects a wide range of host cells and its tropism varies depending on the cell 
types used for propagation [16, 36-42].  To examine the breadth of HCMV peptide inhibition, we 
tested peptide blockage of infectivity using fibroblasts from another tissue (HFF), endothelial 
cells (HAEC), and epithelial cells (ARPE-19).  Both p5R and p5RD, when added at least 30 
minutes prior to infection, reduced HCMV infection by >80% in all cell types (Figure 1.1B). 
Although similar to each other, both were more efficient at preventing HCMV infection in 
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fibroblast cells (~10% more effective) than on other cell types.  This is in contrast to the 
previously characterized p5+14, which was most effective on ARPE-19 cells [26].  This implies 
that these peptides could be binding different HS moieties on different cells. Previous data show 
that p5R has a higher affinity for heparin, amyloid, and blocks MCMV infection 2x more 
efficiently than p5 [26, 34, 35]. These data suggest peptides containing arginine in place of lysine 
may bind to an HS that is important for HCMV entry into different cell types. Our results 
demonstrate that both p5R and p5RD have similar IC50 values and efficiency to reduce HCMV 
infection in different cell types in vitro.  
Proteolytic stability of p5RD 
D-form peptides are resistant to many of the body’s proteases. This proteolytic resistance 
would prolong peptide survival within the host and potentially increase its efficacy [24].  To 
measure the proteolytic stability of p5RD, we incubated both peptides with trypsin and elastase 
serine proteases. Peptides p5R and p5RD were pre-treated with the different proteases for 30 or 
60 minutes.  After which, the peptides were added to cells 30 minutes prior to the addition of 
virus.  Peptide p5RD retained its ability to limit HCMV infection by ~90%, whereas p5R 
exhibited only a 20% inhibition after incubation with the serine proteases (Figure 1.2A and B).  
To mimic a biologically relevant environment, peptides were also incubated in human serum or 
FBS for 30 minutes or 60 minutes prior to addition to MRC-5 cells.  Under these conditions, 
peptide p5RD reduced HCMV infection by 90% after incubation with FBS while p5R was no 
longer inhibitory (Figure 1.2C).  Similarly, p5RD incubated with human serum reduced HCMV 
infection by ≥85%, while serum incubated p5R only achieved a 50% reduction (Figure 1.2D).  
The differences between human serum and FBS treatment could be due to differences in protease 
concentrations or other inhibitors of the peptide/HS interaction [43].  These data suggest the D-
amino acids in p5R protect it from proteolysis making it a better option for in vivo evaluation.  
Efficacy of p5RD in vivo 
. Our data suggests that p5RD effectively reduces HCMV infection and was resistant to 
serum proteases and degradation when exposed to serum.  Before evaluating the anti-viral 
efficacy in mice we characterized the peptide’s biodistribution in healthy animals. 
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Biodistribution experiments of 
125
I-labeled peptide in BALB/c mice showed that, 
125
I-p5RD was 
retained at high levels in the spleen, liver, and kidneys of mice for at least 24 hours post injection 
(Table 1.1).  In contrast, the majority of 
125
I-p5R was excreted or degraded by 4 hours.  Only 
radioiodide, which is liberated during renal and hepatic catabolism of the peptide, is visible in 
the stomach of the mice. To assess the anti-viral efficacy of p5RD in vivo, cohorts of mice were 
injected i.v. with 500 μg of p5RD or PBS at 1, 2, or 4 hour prior to i.p. administration of MCMV 
(1x10
6
 pfu).  The spleen and liver, which are sites where peptide p5RD was retained for >24 h, 
were harvested 4 days post infection (dpi) for titering of virus.  The p5RD-treated mice show 
reduced viral titers for both the liver and spleen when the animals were treated with peptide prior 
to infection (Figure 1.3). However, the greatest reduction occurred in the spleen (~25% 
reduction) when the peptide was administered 1 hour prior to infection (Figure 1.3C).  There is a 
statistically significant reduction of the viral load in the spleen and liver with ~15 -25% decrease 
in viral titers between peptide treated and PBS treated mice at all timepoints.  
To address whether peptide p5RD was capable of inhibiting initial MCMV entry but 
failing to inhibit the subsequent infection of new cells days after administration, we focused on 
the infection of peritoneal exudate cells (PECs) early after infection. 500 μg of peptide was 
administered i.v. 4 or 1 hr. prior to i.p. infection of MCMV.  The PECs were harvested 2 hrs. 
post infection and washed to remove excess virus. An infectious centers assay was used to 
measure infected PECs.  Our data show that administration of peptide 4 hrs. (Figure 1.4A) or 1 
hr. (Figure 1.4B) prior to infection significantly reduced the number of infected PECs (p = 0.007 
and 0.003, respectively), suggesting that p5RD likely inhibits the initial entry of MCMV into host 
cells. 
Peptide efficacy against GCV
R
 HCMV 
The long-term use of antivirals has contributed to the development of HCMV resistance 
to the current antivirals [13].  For example, it is estimated that between 2-27.5% of HCMVs are 
now resistant to GCV [44-47].  We next examined the efficacy of peptide p5RD as an inhibitor of 
infection using GCV
R
 HCMV.  Bacterial artificial chromosome (BAC)-derived HCMVs with 
mutations in either the UL54 gene (T3429) that encodes the DNA polymerase targeted by GCV 
or the viral UL97 gene (T3252) that encodes the kinase required for phosphorylation of GCV 
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were tested against p5RD.  These point mutations are representative mutations found in clinical 
isolates and incorporated into these BAC derived strains [29-31, 48].  Notably mutations in UL54 
also confer resistance to CDV and FOS [13]. We tested the hypothesis that mutations that 
contribute to GCV resistance would not confer “resistance” to the inhibitory effects of the p5RD 
peptide treatment.  First, we confirmed, using the SEAP assay, that T3429 and T3252 strains are 
resistant to high concentrations of GCV (Supplemental Table 1.S1) [31, 32].  To test the efficacy 
of peptide p5RD at inhibiting these GCV-resistant viruses, MRC-5 cells were treated with 200 
µM peptide prior to infection.  Using the SEAP assay to quantify infection as a surrogate for the 
conventional plaque assay, treatment with p5RD reduced the infection of MRC-5 fibroblasts by 
recombinant GCV
R
 HCMVs, (T3429 and T3252) by ~80% (Figure 1.5A).  
GCV
R
 HCMV has been isolated from organ transplant recipients as well as other settings 
[2, 3, 13, 14, 49].  Given that peptide p5RD reduced the infectivity of recombinant GCV
R
 HCMV 
in vitro, we next tested whether this peptide was similarly effective on clinically isolated GCV
R
 
HCMV.  These strains, from patients CH-13 and CH-19, were isolated from seropositive 
recipients during lung transplantation [14].  The strain from patient CH-19 (CH-19) has a point 
mutation A594V making it GCV
R
.  Notably T3252 recombinant virus from the previous 
experiment (Figure 1.5A) contains the same point mutation, A594V. The CH-13 A isolate (CH-
13 A) contains a deletion in codons 597-603 within the UL97 gene which confers resistance to 
GCV [50]. Using the in vitro plaque assay, peptide p5RD reduced CH-13 A and CH-19 infection 
of MRC-5 cells by >84% (Figure 1.5B).  
Synergistic effects of GCV and p5RD 
Prolonged use or high concentrations of GCV, FOS, and CDV leads to kidney damage 
[12].  Treatment of GCV
R
 HCMV requires 2 to 10 fold more GCV
 
in order to inhibit viral 
replication [14, 49].  To examine the synergistic effect of both with p5RD and GCV treatment 
MRC-5 cells were incubated with either GCV, p5RD, or a combination of GCV and p5RD at 
decreasing concentrations of GCV.  Cells treated with 3 μM of GCV alone showed ~95% 
reduction in HCMV infection (Figure 1.6).  Similarly, cells treated with 200 μM of p5RD showed 
~90% reduction in HCMV infection (Figure 1.1 and 1.6).  The combination therapy of p5RD 
(200 μM) and GCV, at either 1.5 μM or 0.75 μM lead to a ≥ 94% reduction in HCMV infection 
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(Figure 1.6). These data suggest that the IC50 value for GCV was reduced when cells are pre-
treated with 200 μM of peptide p5RD prior to infection. The combination of the two anti-CMV 
treatments should reduce prolonged GCV usage, making the development of GCV
R 
HCMV less 
likely and limiting GCV’s toxic side effects. 
Discussion 
Generation of an effective reagent, such as a synthetic peptide, that prevents cellular 
tethering of CMV and thereby hindering infection would benefit 20 to 60% of transplant patients 
that are at risk for developing HCMV disease [44].  Furthermore, an effective prenatal 
prophylactic anti-CMV peptide will benefit the 0.5% to 2% of newborns at risk for contracting 
HCMV in utero [5].  Novel treatments for HCMV must address host organ toxicity and antiviral 
resistance currently associated with GCV, CDV, and FOS treatments.  The current study aims to 
address those concerns by testing the ability of a D-amino acid, proteolytically-resistant peptide, 
p5RD, to reduce CMV infection.  Our data show that p5R and p5RD reduce HCMV infection of 
not only fibroblasts, but also endothelial and epithelial cells in vitro (Figure 1.1). A broad 
spectrum CMV inhibitor is important as CMV has an expansive cell-type tropism for replication 
and latency [16].  While p5R and p5RD reduce HCMV infection in all cell types, there are subtle 
differences in the percent reduction that potentially reflects differences in HS expression on the 
cell. It is known that CMV uses a 6-O-sulfated and 3-O-sulfated heparan sulfate for entry [21, 
22].  Our data suggest that p5RD binds to a specific subset of HS, that is different from HS 
targeted by the previously characterized p5+14 and the HSV-1 entry inhibitor peptide, G2 [25, 
26].  This is supported by our previous observation that, in contrast to p5RD, 
125
I-labeled p5+14 
is not retained in the kidneys, liver, and spleen of WT mice at high concentrations for >4 h post 
injection [51]. 
In order for p5RD to effectively reduce CMV infection in vivo, it must resist hydrolysis 
from host proteases. Our data indicates that the anti-CMV function of p5RD, but not p5R, was 
unaffected after incubation with the serine proteases, trypsin and elastase, or with bovine or 
human serum (Figure 1.2).  Using radiolabeled peptide, we also show that p5RD is retained in the 
spleen, liver, and kidney of WT mice for >24 h while the L-form, p5R, is rapidly dehalogenated 
46     
 
and/or excreted.  These data suggest that the D-amino acids used to synthesize p5RD confer 
protection from hydrolysis and enhances its potential to reduce HCMV infection in vivo.  
In our in vivo experiment, p5RD was administered i.v. before i.p. MCMV infection. 
Peptide was administered i.v. to mimic clinical administration of antiviral reagents. Additionally 
i.v. administration results in widespread biodistribution of p5RD (Table 1.1). MCMV i.p. 
injection results in a systemic infection that involves a variety of tissues and organs [52].  In a 
systemic infection model of MCMV infection followed by primary dissemination to the spleen 
and liver, we found that p5RD reduces infection in these organs at 4 dpi. There are several 
possible explanations for why the reduction was not as great as the in vitro reduction. One 
possibility is that CMV infects host cells by a variety of mechanisms including cell-to-cell spread 
or pH-dependent endosomal entry, which do not require cell surface HSPGs [16, 53-57].  
MCMV intra-tissue spread is mediated by a specific glycoprotein complex (gH/gL/MCK-2) that 
differs from the glycoprotein complex (gH/gL/gO) used in initial MCMV entry [58].  The 
MCMV gH/gL/gO complex is responsible for entering fibroblasts through a fusion event, which 
presumably initially involves HSPG tethering [59]. The MCMV gH/gL/MCK-2 complex 
facilitates infection in macrophages via the endocytic pathway [37, 58].  It is not known whether 
this utilizes HSPGs for entry.  If intra-tissue spread occurs without the use of HSPGs, p5RD 
would be ineffective at reducing infection of tissue cells in vivo.  Another possible explanation 
for p5RD’s lack of efficacy in vivo could be due to its lack of efficacy once infection has been 
initiated.  At 4 dpi MCMV has likely undergone at least two rounds of exponential replication 
[60].  Even at 90% reduction of infection, two rounds of growth would only decrease the viral 
load by little more than a log, which is at the limit of detection of plaques assay.  Whether this 
degree of reduction in viral load would result in reduced pathology in the humans, remains open 
to speculation. 
Another factor that could affect p5RD efficacy is the turnover rate for the HS ligand that 
to which it binds.  The turnover rate for HS and HSPGs is relatively rapid (T1/2 <4 hours) for 
murine epithelial cells [61]. To examine whether p5RD limits initial MCMV entry, mice were 
injected with p5RD prior to MCMV infection of PECs early after infection [62].  We chose an 
i.v. treatment with p5RD in order to be consistent with previous data (Figure 1.3 and Table 1.1) 
and to mimic potential clinical utility.  Peptides are small enough to penetrate blood vessel walls.  
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Therefore, we predicted p5RD would still be able to access the virus in the peritoneum [63].  An 
infectious centers assay revealed that p5RD significantly reduced the amount of infected PECs 
when administered 1 or 4 hours before MCMV infection (Figure 1.4).  While ~50% of PECs are 
macrophages [64], we did not assay whether the peptide is active against macrophages, their 
subsets, or other cells found in peritoneal cavity.  Thus, the timing of p5RD administration 
appears to be important in vivo which may be due to the relatively quick turnover rate of HSPGs 
on different cell types. 
The increasing frequency of GCV
R
 HCMV has warranted the development of novel 
therapeutics and approaches to dealing with CMV infection [13, 14, 48, 65, 66].  The current 
HCMV antiviral agents target and prevent viral DNA replication [67].  Given this clinical need 
we hypothesized and demonstrated that p5RD could inhibit GCV
R
 HCMV infection of cells 
because the peptide is thought to inhibit HSPG-mediated viral entry instead of viral DNA 
replication (Figure 1.5).  Often HCMV antiviral agents are used to treat organ transplant 
recipients for months following transplantation [13, 14, 48, 65].  Among transplant recipients 
and AIDS patients there is a 5%-10% rate of therapeutic resistance [14]. Therefore peptides such 
as p5RD and similar reagents that act by inhibiting the initial CMV-cell interaction may provide 
new benefits for these patients.  In addition, we have demonstrated that p5RD may be effectively 
used in combination therapy with traditional anti-CMV nucleoside analogs, such as GCV.  Pre-
treatment using p5RD would require less GCV to achieve therapeutic benefit.  This would 
decrease the likelihood of developing GCV-resistant strains of HCMV and minimize the organ 
toxicity associated with high concentrations of GCV.  This peptide, and similar reagents, could 
provide the basis for a novel approach to treating CMV diseases. 
.  
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Appendix: Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. in vitro analysis of p5R  and p5R
D.
 (A) The IC
50 
was determined by 
adding successive peptide concentrations (10μM, 50μM, 100μM, 200μM, and 
250μM)  to MRC-5 cells 30 minutes prior to the addition of virus. (B) 200μM of 
p5R and p5RD, were added to either MRC-5, HFF, ARPE-19 or HAEC cells 30 
min prior to the addition of virus . Data represents the average of the percent 
reduction compared to PBS-treated control from three separate experiments with 
three replicates in each experiment ±SD. 
53     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.2. Proteolytic stability of p5R and p5R
D
. 200μM of each peptide was 
pre-treated with 100μg/ml of trypsin, elastase, fetal bovine serum (FBS) or 
human serum for 30 minutes and 60 minutes. Protease treated peptides were 
added to MRC-5 cells 30 minutes prior to the addition of virus. Data represents 
the average of the percent reduction compared to PBS-treated control three 
separate experiments with three replicates in each experiment. Statistical 
significance determined by 2 way ANOVA with Bonferroni posttest:  * p-
value<0.05, ** p-value<0.01, *** p-value<0.001 ±SD. 
A B 
C D 
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p5RD       
balb/c mice 2hpi   balb/c mice 24hpi  
 Tissue distribution 
(%ID/g) 
 Tissue distribution 
(%ID/g) 
 AVERAGE SD   AVERAGE SD 
       
muscle 0.17 0.03  muscle 0.07 0.01 
liver 40.04 5.06  liver 35.69 1.28 
pancreas 0.28 0.04  pancreas 0.12 0.01 
spleen 7.86 1.50  spleen 6.87 0.60 
L kidney 50.90 6.40  L kidney 46.29 2.08 
R kidney 56.02 8.73  R kidney 48.76 4.68 
stomach 1.64 0.27  stomach 0.51 0.14 
up intestine 0.91 0.13  up intestine 0.44 0.00 
low 
intestine 
0.64 0.07  low 
intestine 
0.30 0.02 
heart 0.66 0.13  heart 0.32 0.01 
lung 3.22 0.40  lung 1.73 0.30 
       
p5R       
balb/c mice 1hpi   balb/c mice 4hpi  
 Tissue distribution 
(%ID/g) 
 Tissue distribution 
(%ID/g) 
 AVERAGE SD   AVERAGE SD 
       
muscle 0.80 0.19  muscle 0.28 0.07 
liver 2.96 0.58  liver 1.25 0.26 
pancreas 2.64 0.77  pancreas 0.70 0.25 
spleen 1.95 0.42  spleen 1.02 0.47 
L kidney 3.72 0.17  L kidney 1.00 0.26 
R kidney 2.97 1.41  R kidney 0.97 0.20 
stomach 19.69 3.52  stomach 5.43 0.58 
up intestine 2.12 0.66  up intestine 0.68 0.18 
low 
intestine 
1.68 0.26  low 
intestine 
0.77 0.08 
heart 1.85 0.43  heart 0.76 0.27 
lung 3.03 0.45  lung 1.02 0.21 
Table 1.1 Biodistribution of p5R and p5RD 
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Figure 1.3. Viral load in spleen and liver of p5R
D
 treated mice. Mice 
were pretreated with 500μg of p5R
D
 or PBS intravenously 4 , 2 , 1 hours 
before infection with 1x10
6
 pfu of WT MCMV (K181). Organs were 
harvested 4dpi.  Data represents the average ± SD of peptide treated or 
PBS-treated control from three experiments with five (A and B) or six 
mices (C) each group. Statistical significance was determined by t-test. NS 
– non significant.  
4 hours 
2 hours 
1 hour 
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Figure 1.4. p5R
D
 decreases PECs infection. Mice were pretreated 
with 500μg of p5R
D
 or PBS intravenously 4 hours (A) or 1 hours (B) 
before i.p. infection with 1x10
6
 pfu of WT MCMV (K181). PECs were 
harvested 4hpi. 2x10
5 
PECs were placed over a
 
confluent layer of MEF 
10.1 cells. Data represents the average ± SD of peptide treated or PBS-
treated control from two experiments with 5 mice each experiment. 
Statistical significance was determine by using t-test: * p-value<0.05, 
** p-value<0.01, *** p-value<0.001.  
A B 
57     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. p5R and p5R
D
 efficacy against GCV resistant HCMV. 200μM 
of p5R
D
 were added to MRC-5cells 30 min prior to the addition of (A) BAC 
recombinant parental, recombinant GCV
R 
RLU determined via SEAP assay 
or (B) clinically isolated GCV
R 
HCMV determined via plaque assay. All data 
sets are representative of three independent experiments with at three to six 
repeats ±SD. 
   
A B 
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Figure 1.6. Combined effects of GCV and p5R
D. 
MRC-5 cells were either 
treated with PBS (control) or 200μM of p5R
D
 30 min prior to the addition of 
virus. After infection, virus media was removed and cells were treated with 
four different GCV concentrations (3μM, 1.5μM, 0.75μM and 0.38μM) or no 
GCV (control). Data represents the average of GCV, peptide, GCV + peptide 
treated or PBS-treated control from four experiments with two replicates in 
each experiment. Statistical significance was determined by 2 way ANOVA 
with Bonferroni posttest:  * p-value<0.05, ** p-value<0.01, *** p-
value<0.001 ± SD.  
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Figure 1.S1. Both p5R and p5R
D
 are not toxic in vitro. 100μM, 200μM or 
500μM of p5R and p5R
D
, 0.1% Triton-x 100 (positive control) or media alone 
(negative control) was added to MRC-5 cells or 24 hours. Cell viability was 
determined using an MTS cell viability assay (Promega). All data sets are 
representative of two independent experiments with at least five replicates in 
each experiment ±SD. 
. 
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Virus name EC
50 
(μM)  SD No. of assays 
WT Pol  2.01 0.15 3 
WT UL97 1.92 0.10 3 
Pol A987G 8.41 1.11 3 
UL97 A594V 7.32 2.17 3 
TB40E 
Luciferase 
1.46 0.25 3 
Table 1.S1. EC
50 
for GCV treatment of BAC-derived recombinant HCMV  
mutants. 
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CHAPTER II 
A LITTLE  COOPERATION  HELPS  MCMV  GO  A  LONG  WAY–CO-INFECTION  
BETWEEN  MCMVS RESCUES A VIRAL CHEMOKINE DISSEMINATION DEFECT 
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A version of this chapter was accepted for publication with revisions in 2016 in J. General 
Virology. Authors include: Pranay Dogra, Mindy Miller-Kittrell, Elisabeth Pitt, Tom Masi, 
Courtney Copeland, Shuen Wu, William Miller and Tim Sparer 
 
My use of “we” in this chapter refers to my coauthors and myself. My primary contributions to 
this paper include (1) researching the topic and (2) performing experiments to generate data for 
figure 2.5, 2.6 and supplemental figures and data for the rebuttal to reviewer’s comments. 
Abstract 
Cytomegaloviruses (CMVs) produce chemokines (vCXCLs) that have both sequence and 
functional homology to host chemokines. Assessment of vCXCL-1’s role in CMV infection is 
limited to in vitro and in silico analysis due to CMV’s species specificity.  In this study, we used 
the murine CMV (MCMV) mouse model to evaluate the function of vCXCL-1 in vivo. 
Recombinant MCMVs expressing chimpanzee CMV vCXCL-1 (vCXCL-1CCMV) or host 
chemokine, mCXCL1, underwent primary dissemination to the popliteal lymph node, spleen, 
and lung similar to the parental MCMV. However, neither of the recombinants expressing host 
or viral chemokines was recovered from the salivary gland (SG) at any time point.  This implies 
that either the virus does not disseminate or grow in the SG. Eliminating the growth defect 
explanation, dissemination to the SG was restored upon co-infection with parental virus and 
infection of immune ablated mice (i.e., SCID, NSG, or cyclophosphamide treated). This recovery 
of SG dissemination could be explained by reduced levels of chemokine expression leading to a 
decrease in NK cells and inflammatory monocytes. The co-infection of recombinant and parental 
viruses reduces consititutive chemokine expression and restores dissemination of the 
recombinants to the SG.  Therefore, we conclude that aberrant expression of the chemokines 
induces cells of the innate and adaptive immune system that curtail the dissemination of the 
recombinants to the SG.  
Introduction 
 Human Cytomegalovirus (HCMV) is a ubiquitous -herpesvirus that is an important 
pathogen in immune compromised individuals and newborns [1-3]. It infects between 50% and 
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90% of the population resulting in largely asymptomatic infections [1]. However, primary or 
reactivated HCMV is a frequent cause of retinitis in AIDS patients [4] and increases the 
incidence of organ rejection and graft versus host disease in transplant recipients [5,6]. Central 
nervous system damage due to congenital HCMV infection affects 5,000-8,000 newborns in the 
U.S. each year [7]. As a result, HCMV is the leading cause of infectious hearing loss and non-
hereditary mental retardation [1]. Understanding HCMV pathogenesis is important for the 
development of an effective vaccine or potential therapeutics.  
  CMVs encode numerous proteins that modulate the host immune system. HMCV 
infection alters the expression of host chemokines [8], but also encodes viral homologs of host 
chemokines and their receptors [9-12]. The virulent strain of HCMV, Toledo [13], produces a 
functional CXC chemokine, vCXCL-1Tol, which binds the chemokine receptors CXCR1 and 
CXCR2 inducing chemotaxis and calcium flux in freshly isolated human peripheral blood 
neutrophils (PBNs) [14,15]. In our previous studies, we have shown that the viral chemokine 
from chimpanzee cytomegalovirus (vCXCL-1CCMV), which is 22% identical and 52% similar to 
the vCXCL-1Tol protein, triggers calcium release and chemotaxis of PBNs [16]. Both viral 
chemokines were shown to upregulate the expression of adhesion molecules on PBNs and 
downregulate neutrophil apoptosis, albeit with different potencies [16]. These findings provide 
circumstantial evidence for a role of vCXCL-1 in activating and recruiting neutrophils to 
facilitate CMV dissemination. Clinical evidence, including the recovery of HCMV from 
neutrophils of immunocompromised patients [17-19] and the presence of neutrophilic infiltrates 
in CMV associated retinitis [20], suggests neutrophils, as well as monocytes [21-23], are 
important in HCMV dissemination. While the species specificity of CMVs limits the direct 
evaluation of vCXCL-1 in HCMV dissemination, the function of vCXCL-1CCMV may be 
representative of its HCMV homolog.  In this study, we wanted to extend our previous in vitro 
findings with vCXCL-1CCMV into an in vivo system.  
MCMV is a well-established animal model of CMV infection and has similar cellular 
tropism and disease manifestations as HCMV [24].  MCMV expresses a chemokine homolog, 
MCK2, which has been shown to increase the inflammatory response in mice and enhance 
dissemination of MCMV to the SG [25,26]. Therefore, MCMV was chosen to characterize the 
role of vCXCL-1CCMV in vivo. To test this in the mouse system, we generated recombinant 
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MCMVs expressing vCXCL-1CCMV and host chemokine, mCXCL1. Our results show that 
expression both the host and viral chemokines is detrimental to the dissemination of the 
recombinants to the SG. We show that NK cells and inflammatory monocytes play a role in an 
innate immune system-mediated blockade of this dissemination. Surprisingly, co-infection with a 
non-chemokine-expressing strain of MCMV restored the chemokine expressing recombinants to 
the salivary gland by tipping the immune response to a more favorable environment for normal 
dissemination of the recombinants.  
Materials and Methods 
Cells and Viruses 
Murine NIH3T3 and M210B4 cells (ATCC) were propagated in DMEM supplemented with 10% 
Fetal clone III (FCIII) (Hyclone), 1% penicillin/streptomycin (Hyclone), 1X NEAA, 1% sodium 
pyruvate (100mM), and 0.5 % HEPES (1M). MEF 10.1 cells (ATCC) were propagated in 
DMEM supplemented with 10% FCIII and 1% P/S and L-Gln.  The parental MCMV strain used 
in this study was MCMV RM4511, [26] which has a 1.7 kb puromycin-green fluorescent protein 
(GFP) cassette inserted into the ie2 region and a double point mutation in the m131 gene 
resulting in a nonfunctional MCK2 protein (Figure S1A).  RM4503 is similar to 4511 except 
with wild-type mck2.  These virusese were obtained from Dr. Edward Mocarski, Emory 
University. For UV inactivation of the virus, 50µl of the stock virus were exposed to UV light in 
a UV crosslinker (Stratagene Stratalinker) at a setting of 1200 for 8 minutes. Complete 
inactivation was confirmed via a plaque assay. 
Mice 
Initially, mice that over express human CXCR2 (hCXCR2) or replace murine CXCR2 
(mCXCR2) with human CXCR2 (hCXCR2) were used.  There was concern that vCXCL-1CCMV 
might not stimulate mCXCR2 as seen with vCXCL-1Tol [27].  The hCXCR2 transgenic BALB/c 
mice express hCXCR2 under the control of the neutrophil-specific, human myeloid related 
protein-8 promoter [27].  In the co-infection experiments, mice that replace the hCXCR2 gene 
with the mCXCR2 gene were used [28]. These mice have normal expression levels of hCXCR2 
in all the appropriate murine cell types. We have subsequently shown that vCXCL-1CCMV can 
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function in normal mice (data not shown), which allowed us to use SCID and NSG mice with the 
appropriate parental controls. 3-4 week old BALB/c, NOD-NSG (NSG) mice were originally 
purchased from Jackson Laboratory (Bar Harbor, ME) and SCID/NCr were purchased from 
Taconic Labs.  All mice were housed under specific pathogen free conditions at the University of 
Tennessee or the University of Cincinnati Medical School.   
Plasmid Constructs 
An EcoRI/PstI digested fragment containing the coding region for vCXCL-1CCMV or host 
mCXCL1 (KC) was cloned into the EcoRI/PstI digested plasmid pcDNA3.1/Zeo immediately 
downstream of the HCMV immediate early promoter (HCMV IE). The 1.2kb HCMV IE-
chemokine fragment was PCR amplified adding the flanking restriction sites and a C-terminal 6-
His tag using the primers: MluI HCMV IE (5’-
CGACGCGTCGATGTACGGGCCAGATATACGCCTTGACATTGATTAT-3’) and SalI 6 His 
(5’ACGCGTCGACTGGTGGTGGTGGTGGTGACCTCCTCC-3’).  After sequence verification, 
the HCMV IE-chemokine cassette was digested with MluI and SalI and cloned into the plasmid 
L120.1. L120.1 has 5’ and 3’ sequences from MCMV IE2 for homologous recombination and a 
gpt expression cassette used for selection of recombinant viruses (C. Meiering, unpublished 
data). 
 
Generation of Recombinant Viruses 
Recombinant viruses were generated using a transfection/infection strategy with subsequent 
selection for the loss of GFP along with gpt expression.  NIH3T3 cells were transfected with 
Drd-linearized L120.1+vCXCL-1CCMV or L120.1+mCXCL1 using Lipofectamine 2000 
(Invitrogen). Three hours post-transfection, the cells were infected with MCMV RM4511 at an 
MOI=3. Transfectants were harvested and passaged twice under selection (mycophenolic acid 
(12.5 g/ml) and xanthine (100 g/ml)). Recombinant viruses were identified by the loss of GFP 
fluorescence and subjected to three rounds of plaque purification. For PCR verification, viral 
DNA was isolated by phenol-chloroform extraction and used for diagnostic PCR. The primers 
used were: RM4511 For (5’-CATTGACGTCAATGGTGGGAAAGTACATGGCG-3’), 
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RM4511 GFP Rev (5’-CCCGACGCGCGTGAGGAAGAGTTCTTGCAG-3’), and HCMV IE 
Rev (5’-GAACTCCATATATGGGCTATGAACTAATGACC). 
In vitro Growth Assay 
NIH3T3 or MEF 10.1 cells were plated in triplicate in a 6-well dish and infected with RM4511, 
RMvCXCL-1CCMV, or RMmCXCL1 for either a multi-step (MOI=0.5) or single-step (MOI=5) 
growth analysis.  Supernatants were collected at the indicated times post infection sonicated prior 
to tittering. Viruses were titered via plaque assay. 
In vitro protein expression 
Aliquots from the single-step growth assay were removed and used to verify chemokine 
expression. Ni-NTA agarose beads were used to isolated vCXCL-1CCMV and mCXCL1 proteins 
from 100 g of total protein. The eluted protein samples were subjected to Western blot analysis 
using the primary anti-6-His antibody (Qiagen) diluted 1:200 and secondary anti-mouse HRP 
antibody diluted 1:2000. Silver staining for the proteins in the supernatant was carried out using 
Pierce Silver Staining Kit (ThermoFisher Scientific) per manufacturer’s instructions. Relative 
concentration of the protein was calculated using ImageJ on the captured images (NIH). 
In vivo Growth of Parental and Recombinant Viruses 
10
6
 PFUs of parental or recombinant viruses were inoculated in the FP or intraperitoneally of 
hCXCR2 transgenic, Balb/c, NSG or SCID mice.  At different times post infection, mice were 
euthanized and their footpads, spleens, liver, lungs, popliteal lymph node, and salivary glands 
were removed. Organs were individually weighed, homogenized, and clarified.  Supernatants 
were titered. 
Leukocyte Infectious Centers Assay 
Assay was performed as described in [29].  Briefly, peripheral blood was harvested and red 
blood cells lysed. Leukocytes were plated onto NIH3T3 monolayers.  After 6 hrs. cells were 
overlayed with CMC media.  Plaques were counted after 7 days. 
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Plaque Formation Assay 
Plaque formation assay on MEF 10.1 cells was used to determine viral titers in the organs. 
Briefly MEF 10.1 cells were plated in a 6 well dish.  Organs were harvested and homogenized. 
The homogenate was serially diluted and added the MEF 10.1 cells and incubated for 1 hr. After 
incubation the diluted virus was removed and cells were overlayed with carboxy methyl 
cellulose (CMC) media and incubated for 7 days. At the end of the incubation period, CMC was 
removed and plates were stained with Coomassie blue and plaques counted. 
Co-infection experiments 
Mice were infected (either in the same foot pad or separate foot pads) or intra-peritoneally with 5 
x 10
5
 PFU each of chemokine expressing recombinants (RMmCXCL1/RMvCXCL1) and 
RM4511 or RM4503 for high titer inoculum experiments, or with 100 PFU of each virus for the 
low titer inoculum experiments. Mice infected separately with chemokine expressing 
recombinants or RM4511/RM4503 served as controls for these experiments. Salivary glands 
were harvested at 14 days p.i. from these mice and virus was titered. Expression of GFP was 
used to differentiate between RM4511/RM4503. Chemokine expressing recombinant virus 
plaques from RM4511/RM4503 were GFP+ and those from chemokine expressing recombinants 
were GFP negative. 
Depletion of Cellular Subsets 
In vivo depletion of cellular subsets was performed using antibodies one day prior to MCMV 
infection and then every three days until harvest. Neutrophils were depleted using 1A8 (anti-
Ly6G) or RB6C (anti-Ly6G/C) antibody (1mg/ inoculation) (BioXcell, West Lebanon, NH). 
Flow cytometry was used to confirm depletion of GR-1hi, Mac-1hi neutrophils (Pharmingen). 
Flow Cytometry 
The  following  fluorochrome-conjugated  antibodies  were  used  to  analyze  the  cellular  
subsets: anti-CD3 (17A2), anti-CD45.2 (104), anti-CD11c (N418), anti-Ly6G (1A8), anti-Ly6C 
(HK1.4) (all from Biolegend); anti-CD49b (DX5) from eBiosciences; and anti-CD11b (M1/70) 
from BD Pharmigen. Cells were analyzed  on  BD  LSR II  flow  cytometer (BD  Biosciences) 
and  evaluated using FlowJo Mac software, version 8.7. 
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Statistical Analysis 
Statistical significance was calculated using one tailed Student’s t test or 1 way ANOVA 
followed by Tukey's or Bonferroni’s Multiple Comparison Test in Prism5 (GraphPad) following 
the recommendations of Vaux et al. [30,31]. A p value < 0.05 was considered statistically 
significant. 
Results 
Construction of the chemokine expressing MCMVs 
Strict species specificity of CMVs requires the generation of a recombinant MCMV to assess the 
function of viral chemokines in the mouse model. Therefore, we generated a recombinant 
MCMV expressing vCXCL-1CCMV (RMvCXCL-1CCMV) to study the role of this chimpanzee 
CMV viral chemokine in viral dissemination in vivo. MCMV expressing mCXCL1 (KC) was 
also generated as a control to evaluate specific effects of the viral chemokine on dissemination.  
mCXCL1 is the murine equivalent of human CXCL-1 (Gro-α) with a high affinity for CXCR2. 
MCMV RM4511 was the parental strain used for construction of these recombinants because 
RM4511 lacks a functional MCMV viral CC chemokine, MCK2.  This will allow us to analyze 
the contribution of vCXCL-1CCMV and mCXCL1 in the dissemination of MCMV in the absence 
of the endogenously encoded chemokine, MCK2 (Figure 2.S1A). 
Recombinant plasmid, L120.1, was modified to contain either the vCXCL-1CCMV or 
mCXCL1 coding sequence under the control of HCMV IE promoter (Figure 2.S1B). This 
promoter has been used to drive expression of other genes inserted in the MCMV genome and 
was chosen to ensure high levels of chemokine expression. We chose to insert the chemokine 
cassette into the ie2 region as it is dispensable for growth of MCMV in vivo [32].  The 
chemokine cassette displaces the puromycin-GFP segment present in RM4511, such that loss of 
GFP expression allowed visual selection of recombinant viruses. 
Following transfection of NIH3T3 cells with Drd-linearized L120.1+vCXCL-1CCMV or 
mCXCL1 and subsequent infection with RM4511, recombinant viruses were passaged twice in 
medium containing mycophenolic acid and xanthine to select for recombinant viruses expressing 
gpt. The loss of GFP expression identified recombinant viruses and each virus was plaque 
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purified three times. Recombination and correct insertion of the chemokine cassette was 
confirmed using PCR (Figure 2.S1C). 
Recombinant MCMVs have similar in vitro growth kinetics and chemokine expression  
To determine whether insertion of the vCXCL-1CCMV or mCXCL1 cassette affected replication 
or spread of the recombinant viruses in cell culture, we setup both single (MOI=5) and multi 
(MOI=0.05) step growth curves. RMvCXCL-1CCMV and RMmCXCL1 replicated as well as 
RM4511 in both assays (Figure 2.S1D), indicating no deleterious effects of the insertion on 
growth of the viruses in cell culture. Immunoblotting Ni-NTA-concentrated supernatants from 
each time point of the single step growth curve was used to detect the temporal expression of the 
chemokines in the supernatants of virally infected cells. Both RMvCXCL-1CCMV and 
RMmCXCL1 proteins were detected in the supernatants beginning at the second day post 
infection (p.i.) and continuing for the duration of the experiment (Figure 2.S1E). 
Dissemination of virus in vivo 
The contribution of vCXCL1 to the replication and dissemination of recombinant viruses in vivo 
was evaluated after infecting mice with RM4511, RMmCXCL1, and RMvCXCL1CCMV in the 
foot pad (FP) and measuring virus in the organs with a plaque assay. Recombinants reached 
similar titers as parental virus in FP, and in organs of primary dissemination (i.e., lymph node, 
lung, and spleen) (Figure 2.1A). However, no recombinant virus was detected in SG at day 7 and 
14 p.i. when the parental virus usually reaches peak titers (Figure 2.1A). To exclude the 
possibility that the dissemination of the recombinant virus to the SG was only delayed, viral load 
in the SG was also measured at day 21 p.i. No recombinant virus was detected even at this later 
time point (data not shown). Similar experiments were performed using i.p. infection to 
determine if the route of infection had any effect on viral dissemination.  Mice infected i.p. also 
had no chemokine expressing recombinants in the SG (data not shown). The lack of 
dissemination of these recombinants to the SG was accompanied by an absence of viremia 
during secondary dissemination (Figure 2.1B).  These data point to a dissemination defect 
affecting viremia and subsequent viral dissemination to the SG. 
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Co-infection rescues dissemination of chemokine expressing recombinants  
Expression of the chemokine genes in the recombinants is under the control the HCMV MIEP 
promoter. This strong and constitutively expressed promoter [33] leads to an aberrant expression 
of the chemokines, adversely affecting the dissemination of the recombinants to the SG (Figure 
2.1A). We hypothesized that during co-infection (i.e., parental + recombinant), the dissemination 
defect would dominate, leading to an inhibition or reduction in the dissemination of parental 
virus to the SG. To test this hypothesis, mice were infected in the same FP with a mixed 
inoculum (1:1 ratio of each parental and chemokine expressing recombinant virus). SGs from 
these mice were harvested 14 days p.i. and the viral load determined. Surprisingly, chemokine 
expressing recombinant viruses were recovered from the SG of mice infected with the mixed 
inoculum (Figure 2.2A). Dissemination of the chemokine-expressing recombinants to the SG 
was also rescued in mice that were infected i.p. with a mixed inoculum demonstrating that the 
route of infection was not critical (Figure 2.S2A).  The rescue of dissemination to the SG is 
independent of MCMV’s expression of its endogenous CC chemokine (MCK2), as both the CC 
expressing RM4503 and mutated MCK2 RM4511 rescue the dissemination of the recombinants 
to the SG (Figure 2.S2B). The rescue in dissemination was not due to higher replication of the 
virus in the FP, spleen, or lung post co-infection nor was it due to higher virus at the site of 
infection (Figure 2.S2C).   In addition, the timing of the infections was critical for the rescue of 
dissemination.  For example, no recombinants were found in the SG when the infection of the 
two viruses was separated by 2 or 7 days (Figure 2.S2D). Taken together, these data indicate that 
the adverse effects of aberrant chemokine expression is nullified during co-infection and the SG 
dissemination rescue is temporally restricted requiring the viruses to interact early during 
infection. 
 
The requirement for interaction at the site of infection during co-infection 
One possible explanation for the recovery of chemokine expressing viruses in the SG, is that 
parental MCMV “interferes” with chemokine expression.  To explore how co-infection rescues 
the dissemination of recombinant viruses to the SG, mice were infected with the two viruses in 
separate footpads on the same day. This would eliminate the possibility of the viruses interacting 
at the site of infection, but still allow them interact at the sites of primary dissemination. Both the 
71     
 
viruses grew to similar levels at in the footpad and primary dissemination sites (Figure 2.S2C). 
However, no chemokine expressing recombinant viruses were recovered from the SG of these 
mice at 14 days p.i. (Figure 2.2B).   
The requirement of the close proximity of the two viruses to mediate the rescue 
phenotype suggests that the viruses may co-infect the same cell at the site of infection.  To test 
this possibility we infected mice with a low PFU mixed inoculum (1:1 ratio of 100 PFU each of 
RM4511 and RMmCXCL1). We only used RMmCXCL1 throughout these sets of co-infection 
experiments because both RMmCXCL1 and RMvCXCL1CCMV gave similar results both in vitro 
and in vivo (Figure 2.1 and 2.2A). Infection with a low PFU inoculum reduces the probability of 
co-infection by greater than 1000 fold and subsequently reduces the dissemination rescue (Figure 
2.2C). In order to directly address whether the viruses co-infect cells at the site of infection, we 
performed infectious centers assay with plastic adherent leukocytes isolated from the FP at day 3 
p.i. from mice infected with high titered mixed inoculum (1:1 mix of parental and recombinant), 
which is schematically described in Figure 2.2D. During the amplification step, we were able to 
detect GFP positive and negative plaques from ~ 49% of purified GFP positive plaques (Figure 
2.2E). Purified GFP negative plaques yield all GFP negative plaques during the amplification 
step in all instances. These results indicate that the two viruses need to be at the same site of 
infection, where they co-infect the same cell. 
Live parental virus is required to rescue the dissemination of chemokine expressing 
recombinant virus 
One possible explanation for the rescue of dissemination of the recombinants to the SG during 
co-infection is that the presence of the parental virus particles, stimulates an immune response 
that overcomes the blockade of dissemination. To explore this possibility, we infected mice in 
the same FP with a mixed inoculum containing a 1:1 mixture of viable RMmCXCL1 or RM4511 
and either UV inactivated RM4511 or RMmCXCL1, respectively. Infection of mice with an 
inoculum containing UV inactivated RMmCXCL1 + Rm4511 did not alter the dissemination of 
RM4511 to the SG (Figure 2.3). However, UV inactivation of RM4511 completely abolished the 
rescue of the dissemination of RMmCXCL1 to the SG (Figure 2.3). These data suggest that live-
replicating parental virus is necessary to mediate the rescue of the chemokine expressing 
recombinants to the SG. 
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The need for recombinant and live parental virus to co-infect the same cells suggests that 
the chemokine expressing viruses might have undergone DNA recombination with the parental 
virus. This could lead to the loss of expression of the chemokine gene and subsequent 
dissemination. PCR and subsequent DNA sequencing of the chemokine gene from recombinants 
isolated from the SG following co-infection shows that they all carry the chemokine gene and 
that there are no point mutations in the ORF (Figure 2.S3A). Additionally, RFLP analysis of 
these isolates showed no overt recombination (Figure 2.S3B).  
Co-infection reduces mCXCL1 production in vitro 
In the absence of any recombination or mutation of the chemokine gene, rescue of the SG 
dissemination defect of the chemokine expressing recombinants result from the reduction in 
chemokine production from the chemokine expressing recombinants during co-infection. To test 
this possibility, we carried out an in vitro co-infection assay. Cells in culture were infected with 
recombinant or parental virus alone or with a mixed inoculum. Supernatants were harvested 
every 24 hrs and silver stained to measure chemokine protein levels.  We observed a reduction in 
the relative expression of the chemokine during co-infection in vitro compared with 
recombinants alone (Figure 2.4A).  In spite of these differences in chemokine expression, there 
was no difference in the viral titers (Figure 2.4B). These data suggest that during co-infection, 
less chemokine is produced in vivo, without any effect on viral load. This reduction could be 
sufficient for dissemination of the recombinants to the SG. 
 
Co-infection alters the immune response to chemokine expressing recombinant viruses  
Both vCXCL-1CCMV and mCXCL1 bind and activate neutrophils via CXCR2 [16, 34]. The 
recruitment and activation of CXCR2 cells could lead to an inflammatory environment that 
prevents normal secondary viral dissemination.  Although there was a slight increase in the 
number of neutrophils recruited to the site of inoculation at day 3 p.i. in mice infected with the 
chemokine expressing recombinants compared to RM4511, it was not statistically significant 
(Figure 2.5A).  In addition, we observed more NK cells in the spleen but not the lungs of mice 
compared to RM4511 infected mice at day 4 p.i. (Figure 2.5B). There was a 2-3 fold increase in 
inflammatory and patrolling monocytes in the lungs of chemokine expressing recombinant 
viruses compared with RM4511 infected mice (Figure 2.5B). To see how this profile changes 
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following co-infection, mice were co-infected with chemokine expressing and parental viruses.  
Although this leads to a reduction in NK cells in the spleen and lung, these were not statistically 
significant (Figure 2.5C).  At the same time there was also a reduction in the number of 
inflammatory monocytes in the lungs, but not the spleens of co-infected mice compared to singly 
infected (RMmCXCL1) mice (Figure 2.5C). Together these data suggest that infection with the 
chemokine expressing recombinant viruses leads to a higher infiltration of NK cells and 
monocytes compared to the parental virus at different sites of viral replication. These cell types 
may interfere with the normal secondary dissemination of the chemokine expressing 
recombinants to the SG. During co-infection, the reduction in the recruitment of these cells to 
sites of infection would then allow for dissemination of the chemokine expressing recombinants 
to the SG. 
 
NK and T/B cell mediated blockade of dissemination of the chemokine expressing 
recombinants 
The chemokine expressing recombinants induce differential recruitment of inflammatory 
monocytes and NK cells suggesting an immune mediated blockade of the dissemination of 
recombinants to the SG. To investigate the extent of this blockade, mice were administered 
cyclophosphamide (cyclo) to deplete immune cells prior to infection [35-37] and dissemination 
of the recombinants was measured in the different organs. We observed no difference in the 
primary dissemination between the chemokine expressing recombinants and the parental virus in 
untreated and cyclo treated mice (Figure 2.S4). However, the chemokine expressing 
recombinants were recovered from the SG of cyclo treated mice albeit to much lower titer 
compared with the parental (Figure 2.6A), with detectable viremia measured at day 4 p.i (Figure 
2.6E left panel). 
 Data from the above experiment provides further evidence for an immune mediated 
blockade of recombinant virus dissemination to the SG. To parse out the contribution of the 
immune cell subsets in this blockade, we depleted neutrophils. Activated neutrophils can trigger 
an inflammatory response capable of clearing recombinant viruses and respond to both of the 
CXC chemokines overexpressed in these viruses [38]. Mice were depleted of neutrophils using 
anti-Ly6G antibody prior to infection with parental and recombinant virus, and viral load was 
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measured in the SG at day 14 p.i. Despite the chemokine expressing recombinants slight 
enhancement of recruitment of neutrophils to the site of infection (Figure 2.5A), neutrophil 
depletion did not restore their dissemination to the SG (Figure 2.6B). These results show that 
neutrophils are not responsible for increased clearance of the recombinants in the SG or the 
dissemination defect observed in vivo. 
Switching to mice with known immune cell defects, we used a series of inbred strains 
that lack immune subsets. NK cells form an important arm of the innate immune response to 
MCMV infection [39-41]. To address their role in our model, we utilized the NSG mouse model, 
which lacks NK cells, T and B lymphocytes [42]. NSG mice were infected with the recombinant 
or parental viruses and the viral load in the SG at day 14 p.i. was measured.  We recovered 
recombinant virus from the SG of NSG mice at day 14 p.i., albeit much less than the parental 
virus (~3 logs) (Figure 2.6C). Note that these viral titers are similar to those in the cyclo treated 
mice (Figure 2.6A).  In addition we observed viremia for the chemokine expressing 
recombinants as well as parental virus in NSG mice (Figure 2.6E right panel). Data from this 
experiment suggests that NK cells play a partial role in preventing the dissemination of the 
recombinant virus to the SG. 
Because NSG mice also lack T and B as well as NK cells, we wanted to address the role 
of the adaptive response plays in the lack of dissemination of chemokine expressing 
recombinants.  In particular, T cells play an important role in controlling CMV infection. While 
CD8+ T cells effectively clear MCMV from organs in the periphery [43], viral clearance from 
the SG is dependent on CD4+ T cells [44,45]. To determine if the adaptive immune response 
could be clearing RMvCXCL-1CCMV and RMmCXCL1 from the SG, SCID mice were infected 
with recombinant or parental virus and viral load was measured in the SGs at day 14 p.i. Here 
again, the chemokine expressing recombinants were recovered from the SG of SCID mice as 
seen in the NSG mice, although not at the same levels as parental virus (Figure 2.6D). This data 
suggests that the absence of RMvCXCL-1CCMV and RMmCXCL1 from the SG may be a result of 
an amplified adaptive immune response to the recombinants. Together, data from these 
experiments suggests that the aberrant production of the chemokines by the chemokine 
expressing recombinants induces an innate (i.e., NK cell mediated) and adaptive (i.e., T/B cell 
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mediated) immune response that is responsible for the lack of dissemination of the chemokine 
expressing recombinants to the SG. 
 
Discussion 
 In our previous study we characterized the CCMV chemokine homolog, vCXCL-1CCMV, 
and demonstrated that it is a functional chemokine, activating and recruiting human neutrophils 
similar to the HCMV chemokine vCXCL-1Tol [16].  Due to the species specificity of CMV, the 
in vivo function of vCXCL-1CCMV is unknown. We have gained significant knowledge about 
HCMV dissemination using the MCMV mouse model [345, 352]. MCMV has similar tropism to 
HCMV [1,9] and both the viruses demonstrate a cell-associated viremia in cells of the 
myelomonocytic lineage such as neutrophils, monocytes, and their precursors [1, 8, 17, 46-48]. 
Although the mechanism and relative contribution of each of these cell types to MCMV 
dissemination in vivo has been studied in some detail, the role of host and viral chemokines on 
this dissemination remains unclear [1, 8, 44, 49]. The MCMV CC chemokine, MCK2, 
contributes to the dissemination of MCMV to the SG while spread to other organs is MCK2-
independent [26]. In this study, we used MCMV RM4511, which does not express functional 
MCK2, to generate recombinant MCMVs expressing viral and host CXC chemokines in order to 
evaluate the impact of vCXCL-1CCMV on viral dissemination 
The primary dissemination pattern of RMvCXCL-1CCMV and RMmCXCL1 was similar to 
RM4511 (Figure 2.1A).  However, the chemokine expressing recombinant viruses were not 
recovered from the SG (i.e., secondary dissemination) (Figure 2.1A). The absence of the 
recombinants from the SG was not due to impaired viral growth. There was no difference in viral 
growth of the recombinants compared to the parental virus at the site of inoculation in the FP or 
the primary dissemination organs (i.e., popliteal lymph node, spleen, and lung (Figure 2.1A)).  It 
is possible that our recombinants are unable to replicate in the SG and carry a mutation in the 
sgg1 gene, which has been shown for other MCMV recombinants with a SG growth defect 
[50,51].  However, this is unlikely for several reasons.  First, the independently generated 
recombinants show a similar dissemination phenotype (data not shown). Moreover, when the 
recombinants reach the SG, as is the case of SCID mice, NSG mice, cyclo treatment or co-
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infected mice, they are able to replicate in the SG (Figure 2.6A, C, and D).  However, we did 
observe defective viremia for the recombinants (Figure 2.1B).  Therefore, the recombinants are 
capable of SG replication and show a dissemination defect. 
It is possible that overexpression of the chemokine leads to an over active immune 
response against the recombinants, which results in their increased clearance from the SG. Viral 
clearance from the SG is CD4+ T cell mediated [44,45].  Chemokine expressing recombinants 
were found in the SG of SCID mice, lacking B and T lymphocytes, supporting this possibility 
(Figure 2.6D). Chemokine expressing recombinant viruses were also found in the SG in NSG 
mice and after systemic immune ablation with cyclo treatment, implicating both the 
innate/adaptive immune system for the SG dissemination defect/clearance (Figure 2.6 A, and C).  
Interestingly, restored viremia for the recombinants in both cases paralleled SG dissemination 
(Figure 2.6E).  Thus, although the recombinants may be susceptible to adaptive immune 
mediated clearance in the SG, they also show an innate immune-mediated defect in SG 
dissemination.   
While working with the co-infection model (i.e., parental + chemokine expressing 
recombinants), we made the serendipitous discovery that the recombinants were able to 
disseminate to the SG even in immune-competent mice (Figure 2.2A).  The rescue of 
dissemination required the two viruses to infect simultaneously and at the same site, as 
separating the infection spatially or temporally did not rescue the dissemination to the SG 
(Figure 2B and Figure 2.S2D).  This localization is required for the two viruses to infect the 
same cell, most likely a monocyte/macrophage population at the site of infection (Figure 2.2C, D 
and E).  Our experiments also show that live replicating virus was required to rescue the 
dissemination of the recombinants to the SG, not just viral particles interfering with chemokine 
expressing recombinant dissemination (Figure 2.3). We show that these viruses do not undergo 
recombination, mutation, or deletion of the chemokine gene while replicating with parental virus 
infected cells (Figure 2.S3).  It is also conceivable that the parental virus reduces the replication 
and/or production of the chemokine from the recombinant during co-infection.  Our in vitro co-
infection assay showed that co-infection did not affect viral growth.  However we did observe a 
modest reduction in the chemokine levels produced (Figure 2.4A).  Therefore, the reduced 
chemokine level seen during mixed infection is not due to less virus production, but to 
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intracellular resource competition [52-58].  We were unable to show this reduction in the 
chemokine levels in vivo due to the limits of chemokine protein detection. We speculate that 
similar to the in vitro set up, intracellular resource competition or gene expression suppression 
within the infected cells could also lead to reduced chemokine levels in vivo and subsequent 
dissemination of the chemokine expressing recombinants to the SG. Our data shows that over-
produced chemokines may recruit or activate cells of innate immune system that are detrimental 
for the dissemination of the recombinants to the SG.  A more physiological level of expression of 
the viral chemokine could allow for evaluation of the viral chemokine in vivo such as expression 
under the control of the MCK2 promoter, which expresses with late kinetics. These viruses are 
currently being constructed. These data also bring up the interesting observation that the immune 
system mediated blockade of dissemination of the chemokine expressing recombinants to the SG 
is not very stringent and a little reduction in chemokine levels seems to be sufficient to tip the 
scales in favor of normal dissemination to the SG. 
Surprisingly, neutrophil depletion did not restore dissemination to the SG (Figure 6B). 
Therefore another innate cell type that expresses CXCR2 that is not depleted with the anti-Ly6G 
antibody could play a role in blocking dissemination of the chemokine expressing recombinants. 
For example, dendritic cells, a subset of monocytes, or NK cells can be induced to express 
CXCR2 and CXCR1 [59-62] and may be involved in this process. Although an exhaustive 
analysis of vCXCL1CCMV receptor usage is lacking, mCXCL1 receptor usage is well-
characterized [63].  As both have the same phenotype in our experiments, this SG dissemination 
defect does not seem to be exclusively a vCXCL1CCMV phenomenon. NK cells play a major role 
in the antiviral response against MCMV [39-41]. BALB/c mice which do not induce NK cell 
activation via the m157-Ly49H axis are susceptible to MCMV infection and show much higher 
viral titers in peripheral organs [64-65].  In our experiments we observed higher numbers of NK 
cells recruited to the site of infection in mice infected with the chemokine expressing 
recombinants (Figure 2.5B).  The activation of the NK cells prevents the dissemination of the 
recombinants. Evidence in support of this premise comes from the following observations (i) Co-
infection is associated with a reduction of NK cells recruited to spleen and lung (Figure 2.5C), 
(ii) There was a significant reduction in the NK cells in mice treated with cyclo (Figure 2.S5), 
and (iii) We observed dissemination of the recombinant virus to the SG in NSG mice, which 
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lack, not only T and B cells, but also NK cells.  The reduction or absence of NK cells correlates 
with reduced inflammation at the site of infection or around the foci during primary organ 
infection, which could benefit virus growth and escape from the organ. 
Recently, Farrell et al. showed that FP inoculations probably spread via the lymphatics 
and that this infection/spread is multi-layered [66].  They show that without the subcapsular 
sinus macrophages, more fibroblasts are infected resulting in higher titers and increased spread.  
In our experiments, we hypothesize that an increase in inflammatory cells blocks the normal 
dissemination of MCMV to the SG.  In mice infected with the chemokine expressing 
recombinants, we observed more inflammatory monocytes in the lungs compared to mice 
infected with the parental virus (Figure 2.5B). Co-infection reduced the number of inflammatory 
monocytes in the lung, while not affecting the number of patrolling monocytes (Figure 2.5C).  
This data supports our hypothesis that the monocytes at the site of infection or around the foci of 
infection are the wrong type when the chemokine is expressed during MCMV infection (i.e., 
more inflammatory rather than patrolling). Although this might not affect viral growth at the site 
of infection, it would adversely affect the dissemination of the virus during viremia.  Preliminary 
experiments adoptively transferring leukocytes isolated at day 3 p.i. from the FP of mice infected 
with parental, recombinant, or a mixed inoculum show that we can recover virus from the SG of 
mice receiving cells from mice infected with parental or a mixed inoculum.  However, no virus 
was recovered from the SG of mice that received cells from chemokine expressing recombinants 
(Figure 2.S6). 
Therefore we propose a model where the virus is carried out of the FP to the organs of 
primary dissemination initially by patrolling monocytes. During infection with the chemokine 
expressing recombinants alone, the over expression of the chemokine in the organs of primary 
dissemination (i.e., spleen, liver, lung) causes an increased recruitment of NK cells to the site and 
an enhanced inflammatory state. This supports the differentiation of inflammatory monocytes to 
M1 macrophages at the site, which do not contribute to the dissemination of the virus to the SG.  
The increased number of inflammatory monocytes may also interfere with the ability of 
patrolling monocytes to gain access to virally infected cells.  During co-infection, there is a 
reduction in chemokine levels without affecting viral titers. The reduced chemokine levels leads 
to less NK cells at the site of infection and a reduction in the inflammatory environment granting 
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patrolling monocyte access to the foci of infection, which then allows for the normal 
dissemination. This model is summarized in (Figure 2.S7). 
Although our results may seem to contradict our original hypothesis (i.e., the expression 
of HCMV CXC chemokines aids dissemination), we have to consider the caveat that our 
chemokine expressing recombinants over express the chemokines.  In reality, the expression of 
the vCXCL-1 gene in HCMV is tightly regulated and expressed with late expression kinetics [14, 
67], and not constitutively, as in the case of our recombinants. CXC chemokines are capable of 
making monocytes adhere to the endothelium [68-70], which could allow them to be infected 
more efficiently. Not only can CMV infect monocytes but the infection increases their life span 
[71], allows them to re-circulate [72], and promotes their differentiation into macrophages [21-
23]. This differentiation then allows for productive infection of the virus in these cell types [73-
75]. Because monocytes play an important role in HCMV dissemination in vivo [70-72], it is 
conceivable that HCMV has evolved to express vCXCL-1 at the stage when the virus is budding 
from the infected cell.  The chemokine-induced halted monocyte is at the right place at the right 
time to pick up the budding virus and once the infected the monocyte re-circulates, it carries the 
virus to distal sites spreading infection within the host. 
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Appendix: Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Overexpression of host or viral chemokine prevents MCMV 
dissemination to the SG.  (A) hCXCR2 transgenic mice were inoculated in the 
footpad with 10
6
 PFU of either RMmCXCL1 (▼), RMvCXCL-1
CCMV
 (▲), 
RM4511 (□). Organs were harvested at the indicated days p.i. and virus titers 
were determined via plaque assay.  Each symbol represents the mean virus titer 
of 5-10 mice (+/- standard deviation). Data is representative of 2 experiments. 
(B) Viremia was measured on PBLs isolated from hCXCR2 transgenic mice. 
Data points represent % infected PBLs from individual mice and the horizontal 
line represents the mean from at least 3 mice for each experiment. The dashed 
line indicates the detection limit (DL) of the assay.  
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Figure 2.2. Rescue of the chemokine expressing recombinant virus 
dissemination to the SG upon co-infection with parental viruses 
requires interaction at the site of infection. (A) Mice were infected 
with 5 x 10
5
 PFU of either parental (RM4511) or chemokine-expressing 
recombinant viruses (RMmCXCL1 or RMvCxCL1
CCMV
) alone or in the 
same FP with a 1:1 mixed inoculum (5 x 10
5
 PFU of each). Viral titer 
was measured in the SG at day 14 p.i. (B-C) Mice were infected with 5 
x 10
5
 PFU of either RM4511 or RMmCXCL1 virus alone, in different 
FPs (B) with 5 x 10
5
 PFU of RM4511 and RMmCXCL1 or in the same 
FP (C) with 1:1 mixed inoculum (low titer) with 100 PFU each of 
RM4511 and RMmCXCL1. Viral titer in the SG was measured at day 
14 p.i. The * indicates viral titers in the SG from mice infected with a 
mixed inoculum. The horizontal line is the median titer from the 
experiment. Each symbol represents the titer from an individual mouse. 
Dashed line indicates the DL of the plaque assay. (D) Schematic 
representation of the infectious centers assay performed on plastic 
adherent leukocytes isolated from the FP of mice infected with a 1:1 
mixed inoculum at day 3 p.i. (E) GFP positive viruses were plaque 
purified from D and subjected to a round of amplification to ascertain 
the presence of GFP negative viruses within these plaques. Data is 
expressed as % co-infected plaques from total GFP positive plaques 
purified.  Bar represents mean from 9 mice + SD. 
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Figure 2.3. The rescue of the dissemination phenotype of the 
chemokine-overexpressing recombinants requires live virus.  
Mice were infected with 5 x 10
5
 PFU of either RM4511 or 
RMmCXCL1 virus alone, or a mixed inoculum (1:1 mix) of UV 
inactivated (UV ia) RMmCXCL1: live RM4511 or UV ia RM4511: 
live RMmCXCL1. Viral titer was measured in the SG at day 14 p.i.  
Each symbol indicates the titer from individual mice. The * 
indicates viral titers in the SG from mice infected with a mixed 
inoculum. The horizontal line represents the mean titer from the 
experiment. The dashed line indicates the DL of the assay.  
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Figure 2.4. Co-infection in vitro reduces the recombinant MCMV 
chemokine levels without affecting viral growth. MEF cells were co-
infected at an MOI of 5 of RMmCXCL1 and RM4511 or each one 
individually.  The supernatant was collected at different time points p.i. 
After 6xHis-tagged chemokine enrichment, proteins were visualized on a 
silver stained SDS PAGE gel.  Graph represents the relative concentration 
of chemokine to the loading control + SD from two experiments. One Way 
ANOVA followed by Bonferroni's multiple comparison test was used to 
compare the data. *** = P < 0.001, ** = P < 0.01, * = P < 0.05 (B) Viral 
titers were measured in the supernatant collected from the in vitro co-
infection assays.  Mixed infection (Mxd) was carried out at a MOI of 10 
(i.e., MOI 5 of RM4511 + MOI 5 of RMmCXCL1). The data is 
representative from 3 experiments. Symbols represent the average titer +/- 
SD. 
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Figure 2.5. Co-infection alters the cellular infiltrate at the sites of 
infection to favor dissemination. Mice were infected in the FP with 1 
x 10
6
 PFU RM4511, RMmCXCL1, or RMvCXCL1. Flowcytometry 
was used to measure the number neutrophils infiltrating the FP at day 3 
p.i. (A)  and NK cells, patrolling and inflammatory monocytes 
recruited (B) into the spleen and the lung at day 4 p.i. (C) Mice were 
infected either singly or at 1:1 of each and analyzed with 
flowcytometry. Bars represent the average of the data from 6-9 mice 
per experiment +/- SEM. One Way ANOVA followed by Tukey's 
multiple comparison test was used to compare the data. *** = P < 
0.001, ** = P < 0.01, * = P < 0.05, NS= non significant. 
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Figure 2.6. Absence of cellular subsets permits dissemination of 
chemokine expressing recombinants to the SG.  (A) Mice were 
treated with cyclophosphamide for systemic immune ablation prior to 
infection with the parental and recombinant viruses alone. Viral titers in 
the SG were measured at days 3, 7, 14 and 18 p.i. (B) Mice were 
depleted of neutrophils using anti-Ly6G antibody and inoculated with 
parental and recombinant viruses alone. (C) NSG mice, which lack T, B, 
and NK cells or (D) SCID mice were inoculated with parental or 
recombinant viruses in the FP or i.p., respectively. For experiments in 
panel B-D the SG from the mice were harvested at day 14 p.i. and the 
virus titered.  Results are from 5-10 mice per infection and are 
representative of 2 or more experiments. Bars represent the mean virus 
titer (+/- SD). One Way ANOVA followed by Tukey's multiple 
comparison test was used to compare the data. *** = P < 0.001, ** = P 
< 0.01, * = P < 0.05.  (E) Viremia as measured on PBLs isolated from 
cyclophosphamide (Cyclo) treated BALB/c mice (left) or NSG mice 
(right). Data points represent the % infected PBLs and the horizontal 
line represents the mean of at least 3 mice for each experiment. The 
dashed line indicates the DL of the assay. 
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Figure 2.S1 Construction and characterization of wild type (WT) MCMV, 
parental MCMV (RM4511), RMmCXCL1, and RMvCXCL1CCMV 
viruses (A) The RM4511 recombinant MCMV contains a double point 
mutation resulting in a missense mutation that converts amino acids CC to GR 
in MCK2.  This in effect creates an MCK2 negative strain.  RM4511 also has a 
puromycin/green fluorescent protein expression cassette (puro-GFP) cassette in 
the ie2 locus. The mCXCL1 or vCXCL-1CCMV expression cassette containing 
a gpt selectable marker was used for selection and replaces the puro-GFP 
cassette.  (B) Schematic representation of the puro-GFP and chemokine 
expression cassettes.  The sizes of the diagnostic PCR products produced using 
the MCMV/GFP primers (2.5kb) and MCMV F/HCMV IE primers (3.0 kb) are 
shown. (C) Three PCR reactions were performed using viral DNA as the 
template. (i) Amplification of either the mCXCL1 or vCXCL-1CCMV gene 
using HCMV IE and 6 His primers. This generates a ~325 bp product 
(mCXCL1) and a ~425bp (vCXCL-1CCMV). (ii) Verification of the loss of the 
puromycin-GFP expression cassette using a primer flanking the 5’ MCMV IE2 
homologous region and a primer within the puromycin-GFP cassette (MCMV 
GFP). This generates a 2.3kb product. (iii) Verification of the correct insertion 
site of the mCXCL1 or vCXCL-1CCMV expression cassette using a primer 
flanking the 5’ MCMV IE2 homologous region and a primer within the 
expression cassette (HCMV IE).  This generates a 3kb PCR product. (D) 
NIH3T3 cells were infected in triplicate with RM4511, RMmCXCL1 or 
RMvCXCL1CCMV at a MOI of 0.05 (multi-step) or 5 (single-step). 
Supernatants were harvested daily for five days p.i. and assayed via a plaque 
assay. (D) Western blot analysis was used to analyze the expression of 
mCXCL1 and vCXCL1CCMV proteins. NIH3T3 cells were infected with 
RM4511, RMmCXCL1, or RMvCXCL1CCMV at a MOI of 5.  Supernatants 
were harvested at the indicated times post infection.  Recombinant proteins 
were enriched using Ni-NTA agarose beads. The eluted protein samples were 
subjected to Western blot analysis using anti-6-His antibody to detect the 6-His 
tagged chemokines. 
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Figure 2.S2. Rescue of dissemination of recombinant viruses upon co-
infection is not affected by route of infection and MCK2 chemokine 
expression. (A) Mice were infected i.p. with either the parental virus (RM4511) or 
recombinant virus alone, or a mixed inoculum (1:1 mix of 5 x 105 PFU each of 
parental and recombinant virus). Viral titer was measured in the SG at day 14 p.i. 
(B) Mice were infected with either RM4503 (i.e., MCK2+) or recombinant 
RMmCXCL1 virus alone or mixed inoculum (1:1 mix of 5 x 105 PFU of each 
Rm4503 and RmMCXCL1) in the FP. Viral titer was measured in the SG at day 
14 p.i. (C) Mice were infected with a mixed inoculum (1:1 mix of 5 x 105 PFU 
each of parental and recombinant virus) in the FP (Mixed) or in different FPs with 
5 x 105 PFU each of RM4511 and RMmCXCL1 (Diff). FP, popliteal lymph node, 
spleen and lungs were harvested at days 3 and 5 days p.i., homogenized and viral 
titer measured. Bars represent titer from 5 mice per group + SEM. (D) Mice were 
infected with 1 x 106 PFU of RM4511 and RMmCXCL1 in the same FP but 
delayed by 2 or 7 days. Viral titer was measured in the SG of these mice at day 14 
p.i. after the second infection. RMmCXCL1->RM4511 = first infection 
RMmCXCL1 and second infection with RM4511, RM45111->RMmCXCL1 = 
first infection RM4511 and second infection with RMmCXCL1. In all experiments 
each symbol represents the titer from a mouse with the horizontal line representing 
the median titer for each group. Dashed line represents the detection limit (DL) for 
the plaque formation assay. The * indicates viral titers in the SG from mice 
infected with a mixed inoculum 
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Figure 2.S3 Recombinant virus isolated from the salivary gland after co-
infection with parental virus does not undergo recombination or mutation 
of the chemokine gene.  RMmCXCL1 plaques were isolated from the SG of co-
infected mice at day 14 p.i and grown in large scale cultures. (A) Phenol-
chloroform extraction was used to isolate viral DNA and sequenced using 
HCMV IE and 6His primers described in materials and methods. The protein 
sequence generated from the resulting DNA sequence and aligned using Web 
based ClustalW (1, 2). Green is the signal peptide sequence, red is the CXC 
motif, blue is the His tag, * = 100% identity of the amino acid at the position 
among the sequences analyzed. (B) RFLP analysis was performed on viral DNA 
isolated from the RMmCXCL1 virus (RMmCXCL1 parental) and SG isolated 
virus following coinfection.  Viral DNA was cut using BstZ17I, HpaI and 
HindIII restriction endonucleases. Predicted restriction fragment sizes of the 
digested viral DNA are indicated on right hand side of each gel. 
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 Figure 2.S4. Primary dissemination of virus in cyclophosphamide 
treated mice. Mice were treated with cyclophosphamide to deplete the 
immune cells prior to being infected in the foot pad with 1 x 106 PFU of the 
parental (RM4511) or chemokine expressing recombinant 
(RMvCXCL1CCMV or RMmCXCL1) virus. Untreated mice were use as 
control. Organs (popliteal lymph node, spleen and lung) were harvested at 
days 3, 7, 14, 18 post infection, homogenized and viral titer measured. Bars 
represent virus titer from at least 5 mice per time point + SEM. Dashed line 
represents the detection limit (DL) for the plaque assay. 
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  Figure 2.S5. NK cells are reduced upon cyclophosphamide treatment of 
mice. Mice were treated with cyclophosphamide to deplete immune cells prior 
to i.p. infection with the viruses. The spleen and lung were harvested at day 4 
p.i., leukocytes were stained for flow cytometric analysis. The graph shows the 
number of NK cells in the spleen and lung of infected untreated and cyclo-
treated mice. Bars represent the average number of NK cells from 5 mice per 
treatment group + SEM. 
Figure 2.S6. Dissemination of virus after adoptive transfer of 
infected leukocytes.  Mice were infected with 1x105 PFU of RM4511, 
RMmCXCL1, or a mixed inoculum consisting of a 1:1 mixture 1x105 
PFU each of RM4511 and RMmCXCL1. Leukocytes were isolated from 
the FP at day 3 p.i. and adoptively transferred to mice via tail vein 
injection. SG from these mice was harvested at day 14 post transfer, 
homogenized, and virus titered. Bars represent average virus titer from 3 
mice per group +/- SEM. 
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Figure 2.S7. A model of how co-infection rescues of the chemokine expressing 
recombinants dissemination. (A) During single infection, the overproduction of 
the chemokine at the site of infection in the primary organs of dissemination 
recruits inflammatory cells (NK and IM) to the site and interferes with normal 
secondary viraemia and subsequent salivary gland dissemination. (B) During co-
infection, the reduction in chemokine levels in the primary organs reduces the 
number of inflammatory cells (NK and IM) to the site and allows PMs to gain 
access to the virus. The infected PMs then disseminate the virus to the SG. Figure 
10 Key: IM = Inflammatory monocyte, PM = Patrolling monocyte, NK = Natural 
killer cells, FP = Foot pad, SP = Spleen, LN = Popliteal lymph node, Lu = Lung 
and Sg = Salivary gland,  =Chemokine; Viruses:  = 
RMmCXCL1/RMvCXCL1CCMV,   = RM4511 
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CHAPTER III 
NOVEL HUMAN CYTOMEGALOVIRUS VIRAL CHEMOKINES, VCXCLL-1S, 
DISPLAY FUNCTIONAL SELECTIVITY FOR NEUTROPHIL SIGNALING AND 
FUNCTION 
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Heo J, Dogra P, Masi TJ, Pitt EA, de Kruijf P, Smit MJ, et al. Novel Human Cytomegalovirus 
Viral Chemokines, vCXCL-1s, Display Functional Selectivity for Neutrophil Signaling and 
Function. JI. 2015. Epub 2015/05/20. doi: 10.4049/jimmunol.1400291. PubMed PMID: 
25987741. 
 
My use of “we” in this chapter refers to my coauthors and myself. My primary contributions to 
this paper include (1) performing experiments to generate data for figure 3.2 and for the rebuttal 
to the reviewers, and (2) researching the topic. 
Abstract 
Human cytomegalovirus (HCMV) uses members of the hematopoietic system including 
neutrophils for dissemination throughout the body.  HCMV encodes a viral chemokine, vCXCL-
1, that is postulated to attract neutrophils for dissemination within the host.  The gene encoding 
vCXCL-1, UL146, is one of the most variable genes in the HCMV genome.  Why HCMV has 
evolved this hypervariability and how this affects the virus’ dissemination/pathogenesis is 
unknown.  Because the vCXCL-1 hypervariability maps to important binding and activation 
domains, we hypothesized that vCXCL-1s differentially activate neutrophils, which could 
contribute to HCMV dissemination and/or pathogenesis.  In order to test whether these viral 
chemokines affect neutrophil function, we generated vCXCL-1 proteins from 11 different clades 
from clinical isolates from HCMV-congenitally infected infants.  All vCXCL-1s were able to 
induce calcium flux at a concentration of 100 nM and integrin expression on human peripheral 
blood neutrophils (PBNs) in spite of differences in affinity for the CXCR1 and CXCR2 
receptors.  In fact their affinity for CXCR1 or CXCR2 did not directly correlate with chemotaxis, 
G protein-dependent and independent (β-arrestin2) activation, or secondary chemokine (CCL22) 
expression. Our data suggest that vCXCL-1 polymorphisms impact the binding affinity, receptor 
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usage, and differential PBN activation that could contribute to HCMV dissemination and/or 
pathogenesis. 
 
Introduction 
Human CMVs (HCMVs) are ubiquitous pathogens that are well adapted to modulate host 
immune responses [1, 2]. HCMV contains genes for immune evasion that function to increase 
viral survival and dissemination and that may contribute to pathogenesis [3]. There are a large 
number of open reading frames (ORFs; ∼82) in HCMV that are nonessential for virus replication 
in vitro, but may have a role in immune evasion in vivo [4, 5]. In one of these regions, the UL/b’ 
region, the ORFs UL146 and UL147 have limited homology to host CXC chemokines [5]. Yet, 
the UL146 protein from the Toledo strain of HCMV, vCXCL-1Toledo, acts as a functional CXC 
chemokine [6] that binds to CXCR1 and CXCR2 and induces neutrophil chemotaxis and calcium 
mobilization [7]. This gene is one of the most variable in the entire HCMV genome [8–12]. This 
variability is localized throughout the entire chemokine, including the N terminus and N-loop 
region, which are important for chemokine receptor binding and activation [13, 14]. Some strains 
even alter the GluLeu-Arg (ELR) prior to the CXC motif, which is critical for receptor 
recognition and activation [15, 16]. We hypothesized that hypervariable vCXCL-1s produced 
from HCMV-infected endothelial cells recruit neutrophils with alterations in binding, activation, 
and neutrophil functions that contribute to viral dissemination and possibly its pathogenesis. 
Eleven distinct vCXCL-1 clades were previously found in clinical isolates from congenitally 
infected infants [17]. In these groups the N-loop region was highly variable. In addition one 
isolate, vCXCL-1TX15, encoded a non-ELR CXC chemokine. Although the genetic variability 
of vCXCL-1 does not correlate definitively with congenital outcomes, the hypervariability within 
the N-loop region suggests that the vCXCL-1s may have different interactions with the 
chemokine receptors CXCR1 and CXCR2. To address functional variability of the vCXCL-1s, 
recombinant vCXCL-1s from each clade were generated. Competition binding, signaling, and 
neutrophil activation assays were used to assess the effect of vCXCL1 variability on chemokine 
function. 
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Materials and Methods 
 
Materials 
DMEM, penicillin, and streptomycin were obtained from Hyclone Laboratories (Logan, UT). 
FBS was purchased from Mediatech (Manassas, VA). DMEM containing 25 mM HEPES and L-
glutamine, OPTI-MEM, Hygromycin B, and Geneticin were obtained from Invitrogen (Paisley, 
U.K.). BSA Fraction V (BSA) was purchased from Roche (Mannheim, Germany). 
Polyethylenimine was obtained from Polysciences (Warrington, PA). 125I-CXCL8 and 35S-
GTPgS was obtained from PerkinElmer Life Sciences (Boston, MA). Clinical isolates used for 
cloning of the vCXCL-1 ORFs were provided by Dr. James Bale (University of Utah School of 
Medicine), Dr. Sunwen Chou, (Oregon Health and Science University), and Dr. Gail J. Demmler 
(Texas Children’s Hospital) as described previously [18]. 
 
Cell culture and CXCR2 transfection 
Insect cells, serum-free adapted SF9 cells (Invitrogen, Carlsbad, USA), were grown at 28°C in 
serum-free Sf-900 II SFM medium (Invitrogen, Carlsbad, USA).  Hi5 cells (Invitrogen, USA) 
were grown in suspension at 28°C in serum-free Insect-XPRESS medium (Lonza, Switzerland).  
Both cells were grown in non-humidified, ambient air-regulated incubator.  
PathHunter
TM
 HEK293-CXCR2 cells (DiscoveRx, Fremont, USA), were grown at 5% 
CO2 and 37°C in DMEM with 25 mM HEPES and L-glutamine supplemented with 10% (v/v) 
heat-inactivated fetal bovine serum, 50 IU/ml penicillin, 50 g/ml streptomycin, 800 g/ml 
Geneticin and 200 g/ml Hygromycin-B.  
HL-60 T2 cell transfectants over-expressing CXCR2 (a kind gift from Dr. Ann 
Richmond, Vanderbilt University, USA) were grown at 5% CO2 and 37°C in RPMI-1640 
Hyclone Laboratories (Logan, Utah) supplemented with 10% (v/v) fetal bovine serum, 50 IU/ml 
penicillin, 50 g/ml streptomycin, 400 g/ml G418 (Mediatech, Manassas, USA).  
For 
35
S-GTPγS experiments, HEK293T cells were grown at 5% CO2 and 37°C in 
Dulbecco’s modified Eagle’s medium supplemented with 10% (v/v) fetal bovine serum, 50 
IU/ml penicillin and 50 g/ml streptomycin.  HEK293T were transiently transfected (per 10 cm 
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dish) with 2.5μg of cDNA encoding human CXCR2 supplemented with 2.5 μg of pcDEF3 by 
using linear polyethyleneimine (PEI) with a molecular weight of 25 kDa as previously described 
(18). 
Neutrophil isolation 
PBNs were isolated from EDTA-treated blood from healthy human volunteers using dextran 
sedimentation and density gradient centrifugation as previously described [19].  Erythrocytes 
were lysed with hypotonic lysis in 0.2% NaCl.  Neutrophils were resuspended in the buffers for 
the individual assays.  Viable neutrophils were quantified with trypan blue exclusion using a 
hemacytometer.  The use of human subjects has been approved by the University of Tennessee 
Institutional Review Board (IRB# 6476B). 
Production of recombinant vCXCL-1 proteins 
The vCXCL-1 gene, UL146, was PCR amplified from HCMV DNA from each of the 11 clades.  
Amplicons were cloned into the baculovirus transfer plasmid 1392 (Invitrogen, Carlsbad, USA), 
which contains homologous regions for recombination into the baculovirus genome.  PCR 
primers were designed to include the open reading frame (ORF) and with an additional 2-4 
glycines and six histidines on the carboxyl terminus of the proteins for purification.  For 
generation of baculoviruses, SF9 cells were transfected with the 1392/UL146 ORF plasmid 
construct and linearized AcNPV DNA (Sapphire Baculovirus DNA) (Orbigen USA) using 
transfection reagent Cellfectin (Invitrogen, Carlsbad, USA).  Recombinant baculoviruses 
containing the UL146 gene were titered and used to infect Hi5 cells for optimum protein 
expression.  48 hrs after infection, cells and supernatants were harvested.  Recombinant protein 
was isolated from the supernatants using Ni-NTA agarose beads (Qiagen, San Diego, USA) and 
resuspended in PBS.  Protein concentration was quantified using silver staining of SDS-PAGE 
gel using lysozyme as a standard and analyzed using Quantity One software (Bio-Rad, Hercules, 
USA).  MALDI-TOF was used to confirmed protein purity and the correct m.w.  
Intracellular calcium mobilization assays 
Release of calcium from intracellular stores was determined on freshly isolated PBNs 
resuspended in Minimal Essential Medium (MEM).  PBNs at 5 x 10
6
 cells/ml were loaded with 4 
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μM Fluo-4, AM (Molecular Probes from Invitrogen, Carlsbad, USA) for 60 min at 37 °C.  Cells 
were then washed once with MEM and incubated for another 30 min for completion of the 
esterification process. Finally the cells were diluted to 1 x 10
6
 cells/ml in MEM and for the 
calcium flux assay.  Chemokines were added to 2 ml of cells at a final concentration of 100, 10 
and 1 nM.  Calcium flux was measured using a Photon Technology International 
Spectrophotometer (Birmingham, NJ, USA) at an excitation of 494nm nm and emission of 
516nm, FeliX32 software for analysis. Relative intracellular calcium levels post stimulation were 
expressed as change in fluorescence = fluorescence after stimulation – background fluorescence 
(Δ Fluorescence) for each of the chemokines tested.  
 
β2 integrin staining 
1×10
6
 cells PBNs were resuspended in RPMI-1640 with 1% FBS and exposed to 100 nM of 
chemokines for 2 h at 37 °C.  Cells were washed with PBS and blocked with 1% goat serum.  
PBNs were incubated with fluorescently conjugated CD11a, CD11b, and CD11c antibodies 
(Caltag Invitrogen, Carlsbad, USA) on ice for 30 min. and fixed with 4% paraformaldehyde.  
Cells were analyzed with flow cytometry (FacsCalibur, BD Bioscience).  
 
Human PBN chemotaxis assays 
Chemotaxis assays were performed on freshly isolated PBNs resuspended in HBSS with 0.1% 
BSA and 10 mM HEPES.  Assays were performed in triplicate in 96-well chemotaxis plates.  30 
μl of chemokines were loaded at varying concentrations (100 and 500nM) into the lower well of 
the modified Boyden chamber (Neuroprobe, Gaithersburg, USA) and fitted with a 5 μm filter. 
PBNs were labeled with 1:1000 CalceinAM (Invitrogen, Carlsbad, CA) for 1hr. on a rotating 
wheel at 37°C.   Cells were washed with PBS and resuspended to 5×10
6
 cells/ml.  20 μl were 
added to the upper well.  The PBNs were allowed to migrate for 2-3 hr. at 37°C.  The number of 
PBNs that migrated to the chemokines was measured on a fluorescent plate reader (Synergy 2, 
Biotek, USA) minus the fluorescence from the buffer only control wells.  
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Receptor binding analysis 
The ability of vCXCL-1s to compete for binding to either CXCR1 or CXCR2 was evaluated as 
previously described (6) [152] [152] [152].  Briefly, 1×10
5
 - 3×10
5
 HEK293 cells stably over-
expressing CXCR1 or CXCR2 were incubated with 100pM 
125
I-labeled CXCL8 (MP 
Biomedical) and increasing concentrations of unlabeled chemokines for 1 hour at room 
temperature.  Cells were collected on glass filters, washed twice, and bound radioactivity was 
measured with liquid scintillation counting.  The graph was plotted and competition constants 
(IC50) were analyzed using GraphPad Prism 5 for Windows.  
35
S-GTPS binding assay 
Two days after transfection with CXCR2 expression constructs, HEK293T cells were detached 
from the plastic surface using ice-cold phosphate-buffered saline (PBS) and centrifuged at 1500g 
for 10 min at 4°C.  The pellet was resuspended in ice-cold PBS and centrifuged.  Cells were 
resuspended in ice-cold membrane buffer (15 mM Tris, 1 mM EGTA, 0.3 mM EDTA, and 2 mM 
MgCl2 , pH 7.5), followed by homogenization using a Teflon-glass homogenizer and rotor.  The 
membranes were subjected to two freeze-thaw cycles using liquid nitrogen, followed by 
centrifugation at 40,000g for 25 min at 4°C.  The pellet was rinsed once with ice-cold Tris-
sucrose buffer (20 mM Tris and 250 mM sucrose, pH 7.4) and subsequently resuspended in the 
same buffer and stored (-80°C).  Protein concentration was determined using a BCA-protein 
assay (Thermo Scientific, Rockford, USA).  
Membranes (2.5 µg/well) were incubated in 96-well plates in assay buffer (50 mM 
Hepes, 10 mM MgCl2, 100 mM NaCl, pH 7.2 with 5 µg saponin/well, 3 µM GDP and 
approximately 500 pM of 
35
S-GTPS added) and the indicated concentrations of CXCL8 or 
vCXCL-1 to a final volume of 100 l.  The reaction mixtures were incubated for 1 hour at room 
temperature, harvested with rapid filtration through Unifilter GF/B 96-well filterplates 
(PerkinElmer, USA) and washed three times with ice-cold wash buffer (50 mM Tris-HCl and 5 
mM MgCl2, pH 7.4).  
35
S-GTPS incorporation was determined using a Microbeta scintillation 
counter (PerkinElmer, USA).  Functional data were evaluated by a non-linear curve fitting using 
GraphPad Prism 4.0 (GraphPad Software, inc., San Diego, CA).  
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-arrestin recruitment assay 
PathHunter
TM
 HEK293-CXCR2 cells were plated out overnight at 1x10
4
 cells/well (384-wells 
format) in 20 l OPTI-MEM.  A pre-incubation with vehicle (PBS + 0.1 % BSA) of 30 min at 
37°C and 5% CO2, was followed by 90 min with CXCL8 or vCXCL-1 stimulation at 37°C and 
5% CO2.  12 l PathHunter Detection Reagents (DiscoveRx, Fremont, USA) was added.  After 
60 min. incubation at room temperature, -galactosidase, as an indicator of -arrestin-CXCR2 
interaction, was measured for 0.3 sec in a Victor
2
 1420 Multilabel Reader.  Functional data were 
evaluated using a non-linear curve fitting using GraphPad Prism 4.0 (GraphPad Software, inc., 
San Diego, CA). 
Quantitative real-time PCR of CCL22 expression 
HL-60 T2 cell transfectants over-expressing CXCR2 were differentiated for 7 days with 1.3% 
DMSO prior to chemokine treatment.  Medium was exchanged with HBSS and incubated with 
viral chemokines at a final concentration of 100 nM for 4 h at 37 °C.  Total RNA was isolated 
with Tri-Reagent (Sigma, St. Louis, USA) and reverse transcribed using ProtoScript M-MuLV 
first strand cDNA synthesis kit (NEB, Ipswich, USA).  Real-time PCR was performed using iQ5 
Real-Time PCR Detection System (Bio-Rad, Hercules, USA) with a reaction mixture volume of 
25 µl containing SYBR green (NEB DyNAmo SYBR green qPCR kit), 300 nM of each primer, 
and ~25ng of cDNA.  Primers for CCL22 were purchased from SABiosciences (Cat # 
PPH00697E).  The reaction conditions were 95°C for 10 min, followed by 40 cycles of 95°C for 
15 sec. and 60°C for 60 sec.  The results were analyzed with the iQ5 Optical System Software 
(Bio-Rad, Hercules, USA).  The relative gene expression levels were calculated as the fold 
change using the formula: Ratio = 2−ΔΔCT, where ΔCTtarget or reference = threshold cycle (CT) of 
the control gene (ACT1) − CT of the target gene (CCL22), and ΔΔCT = ΔCTreference − ΔCTtarget 
[20].  The housekeeping gene encoding actin (ACT1) was used as a reference control. Primers 
for ACT1 were 5’-TGAGATGCATTGTTACAGGA-3’ (forward) and 5’-
CACGAAAGCAATGCTATCAC-3’ (reverse) generating a 120-bp product. 
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Results 
Amino acid sequence alignment 
Previously, we sequenced the UL146 gene from 51 clinical isolates and showed that it comprised 
11 genetic clades [161].  Representative isolates from the 11 clades were aligned with vCXCL-1 
from the Toledo strain (vCXCL-1Toledo) (Figure 3.1).  The percent identities of the mature forms 
of the vCXCL-1s, without the signal sequences, vary between 23.7% - 61.2% compared to 
vCXCL-1Toledo.  The vCXCL-1s contain ~20 additional residues on the carboxyl terminus 
compared to host chemokines CXCL1 and CXCL8, but the function of these extra residues is 
unknown.  Alignment of the vCXCL-1s and the host chemokines show seven conserved 
residues, including the arginine (R) in the ELR motif, two cysteines (C) in the N-terminus (part 
of the CXC motif), a proline (P) at position 32, cysteines at position 35 and 55, and a leucine (L) 
at position 56.  Furthermore, all vCXCL-1s contain a glycine (G), valine (V), histidine (H), 
tryptophan (W) and proline (P) at position 21, 54, 60, 65 and 87, respectively, which are lacking 
in the host chemokines.  The ELR motif was conserved in all except vCXCL-1TX15.  The 
variability in the N-loop region [21][409], C-terminus [22, 23], and even in the ELR motif [24], 
led us to evaluate differences in chemokine receptor binding and functional responses [25][410].  
 
vCXCL-1 production using the baculovirus expression system 
In order to address functional differences between the vCXCL-1s, we generated recombinant 
vCXCL-1s using the baculovirus protein expression system.  Unlike protein production from 
prokaryotes, baculovirus expression provides mammalian signal-sequence cleavage, eukaryotic 
glycosylation patterns and protein folding.  Because some vCXCL-1s contain multiple predicted 
signal cleavage [6][152] and glycosylation sites, and differences in recombinant protein refolding 
conditions, we chose to express and purify them using the baculovirus system.  All vCXCL-1s 
were 6 His-tagged and purified using Ni-NTA agarose beads.  Purity was confirmed with matrix-
assisted laser desorption/ionization-time of flight (MALDI-TOF) and resulted in the predicted 
molecular weights (11-15 kDa). 
106     
 
vCXCL-1s stimulate calcium release in PBNs 
Release of intracellular calcium is a common indicator of chemokine activation of PBNs [6, 
26][152, 354].  CXCL8 and CXCL1 were shown to induce calcium flux at similar concentrations 
via CXCR2 [27].  To investigate vCXCL-1’s activation of PBNs, vCXCL-1s from the different 
strains were added to freshly isolated PBNs.  All vCXCL-1s induced calcium flux at a 
concentration of 100 nM including 100751, which is not shown in Figure 3.2. However they 
differ in their ability to induce a calcium flux at other concentrations tested (Figure 3.2). This 
demonstrates that even though the viral chemokines can induce calcium mobilization in PBNs, 
the different vCXCL-1s have differing sensitivities for calcium signaling that may induce 
differential downstream activation of PBNs.  
vCXCL-1s upregulate CD11b and CD11c  
β2 integrins are receptors that form heterodimers composed of an α component, such as CD11a, 
CD11b, and CD11c, and a β component, CD18.  They are present on circulating leukocytes and, 
once the cell is activated, initiate adhesion to endothelial cells and subsequent transmigration 
across the endothelium [28].  Host chemokine, CXCL8, upregulates CD11b and CD11c 
expression [29, 30].  Moreover, vCXCL-1Toledo and the vCXCL-1 from chimpanzee CMV also 
increases integrins on PBNs [26].  In this study, we tested the ability of vCXCL-1s to alter the 
surface expression of these receptors on PBNs (Figure 3.3).  Exposure to the vCXCL-1s or host 
chemokines, CXCL1 and CXCL8, does not change cell surface expression levels of CD11a.  
However, CD11b and CD11c levels are increased upon exposure to either the vCXCL-1s or host 
chemokines.  The percent change in the mean fluorescent intensity of CD11b was 57-91% for the 
viral chemokines, which similar to CXCL1 upregulation (82%) but less than CXCL8 (143%).  
Likewise, the percent change of CD11c varied from 35-55% for the vCXCLs, which is similar to 
CXCL1 (43%) but lower than CXCL8 (80.3%). These results demonstrate that the viral 
chemokines selectively induce β2 integrins (CD11b and CD11c) upregulation but without 
significant differences between them at 100nM. 
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Differential migration of human PBNs 
Both CXCL8 and vCXCL-1Toledo are potent chemoattractants for PBNs [15, 26][152, 411].  Even 
though there were no differences in calcium flux and integrin expression, these readouts could 
have a lower threshold for activation compared to a more complex PBN function like migration.  
We quantified the PBNs that chemotaxed to different vCXCL-1 concentrations and found 
differences in their migratory ability (Figure 3.4).  All vCXCL-1s except vCXCL-1TX24 and 
vCXCL-1TX15 induce migration at 500nM while at 100nM only vCXCL-1C952, vCXCL-1E760, 
vCXCL-1Toledo, vCXCL-1100751, and vCXCL-1C956 could stimulate migration. This is the first 
time that differences between the different vCXCL-1s were observed in a functional assay. 
Affinities for CXCR1 and CXCR2 
Because some CXC chemokines such as CXCL8 bind to both CXCR1 and CXCR2 and these 
receptors are important for chemotaxis [31-33], we investigated receptor usage and affinity of the 
different chemokines for CXCR1 and CXCR2.  Competition binding assays using the vCXCL-1s 
to displace 
125
I-CXCL8 on HEK293 cells expressing either CXCR1 or CXCR2 (Figure 1.5) 
showed IC50 concentrations that ranged from 2.6 - 148.7 nM for CXCR2 and 3.3 nM to > 1,000 
nM (i.e. no competition) for CXCR1.  Using cluster analysis of the averages of the different 
IC50’s we divided the chemokines into high, medium-high, medium-low, and low affinity binders 
for CXCR2 (Figure 3.5A).  The group of high affinity binders (2.6 - 3.6 nM) along with CXCL8, 
are vCXCL-1Toledo and vCXCL-1C952. Medium-high affinity binders (11.3 - 18.6 nM) are 
vCXCL-1Tx11, vCXCL-1E760, vCXCL-1C956, vCXCL-1100751 and medium-low members are 
vCXCL-1102410, vCXCL-1Tx24, vCXCL-1C954 (32.7 - 55.5 nM).  The low affinity group (> 141 
nM) contains only two members, vCXCL-1Towne and vCXCL-1Tx15.  Interestingly, the viral 
chemokines with high affinity for CXCR2 (vCXCL-1Toledo and vCXCL-1C952) have weak binding 
to CXCR1 compared to the host chemokines. Generally the higher the affinity for CXCR2 the 
more likely the viral chemokines will bind to CXCR1 (Figure 3.5B).  The medium-high CXCR2 
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binders generally do not bind to CXCR1 except for vCXCL-1E760.  These data indicate that the 
viral chemokines bind with differing affinities for CXCR2 with weak to no binding to CXCR1.  
All vCXCL-1s regardless of their affinity for CXCR1 or CXCR2 (except vCXCL-1TX24 and 
vCXCL-1TX15) induce migration above the limit of detection at 500nM.  At the lower 
concentration (100 nM) only the high affinity or the select medium-high affinity binders (i.e., 
vCXCL-1E760, vCXCL-1100751 and vCXCL-1C956) could induce migration (Figure 3.4).   
This data implies that affinity for CXCR2 (i.e., high affinity equals high migration) 
and/or CXCR1 usage are potential factors in PBN migration [32, 33][64, 412]. Because it is not 
strictly correlated with affinity, differential agonist activation signals could also contribute to 
PBN migration as well.  
vCXCL-1s induce differential 
35
S-GTPγS binding and β-arrestin2 recruitment 
Chemotactic responses can be mediated via G-protein dependent and/or G-protein independent 
signaling.  Berger et al [30] demonstrated that CXCL8-induced β2 integrin CD11b upregulation 
and migration of neutrophils is Gαi dependent.  Chemokine-induced calcium flux involves Gαi 
proteins as well [34, 35].  Based on these studies and observation of differences in migration and 
binding, we investigated whether vCXCL-1s display differences in G-protein dependent and 
independent signaling that could explain the differences in migration. 
35
S-GTPγS binding 
experiments were performed on HEK293T membranes expressing human CXCR2 (Figure 3.6A-
B).  The pEC50 value of CXCL8 in this assay is 6.9.  Only CXCL1 and vCXCL-1Toledo are able to 
reach a maximal response equivalent to 1 µM CXCL8. vCXCL-1Toledo is a high affinity CXCR2 
agonist capable of inducing migration (Figure 3.6) and uses G proteins (Figure 3.6A).  
Surprisingly, vCXCL-1C952, another high affinity binder of CXCR2 that induces PBN migration 
does not induce a G protein response.  All those with medium-affinity for CXCR2, except for 
vCXCL-1TX11, have medium potency for G protein binding, regardless of their ability to induce 
migration.  vCXCL-1TX11 has a medium-high affinity for CXCR2 and induces PBN migration 
but does not use G proteins for inducing this response.  As expected, those with low affinity for 
CXCR2 had no GTP binding (vCXCL-1Towne and vCXCL-1TX15).  Based on the dose response 
curves, we propose a potency order of the chemokines for CXCR2: CXCL8 ~ CXCL1 ~ 
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vCXCL-1Toledo ≥ Intermediate: vCXCL-1E760, vCXCL-1100751, vCXCL-1C956, vCXCL-1102410, 
vCXCL-1TX24, vCXCL-1C954 > vCXCL-1C952. No response: vCXCL-1Towne, vCXCL-1TX11, 
vCXCL-1TX15. These results illustrate that the different vCXCLs use G protein dependent 
mechanisms that correlate with affinity for CXCR2 except in two cases (vCXCL-1C952 and 
vCXCL-1TX11). 
Traditionally, β-arrestin proteins were thought to function only to desensitize activated 
GPCRs. However, in the last decade β-arrestins were shown to induce intracellular signaling as 
well [36, 37].  The involvement of β-arrestins in chemokine-induced chemotaxis was first 
described for the CXCR4/CXCL12 axis [413] and involves the p38 MAPK pathway [38].  
Following from these studies, a role for β-arrestin2 in CXCR2 directed chemotaxis was shown 
[23, 40, 41].  β-arrestin2 induced chemotaxis could explain the differences seen with the 
different chemokines (Figure 3.6).  To measure chemokine-induced β-arrestin2 recruitment, we 
used the PathHunter-HEK293-CXCR2 indicator cell line, which produces a functional β-
galactosidase in response to β-arrestin2 [42].  The pEC50 value of CXCL8 in this assay is 9.1. 
Figure 3.6C-D shows that CXCL8, CXCL1, vCXCL-1Toledo, vCXCL-1C952 and vCXCL-1E760 
make full dose-response curves, whereas the other viral chemokines display incomplete curves 
or no β-arrestin2 signalling.  Based on these data the potency order of the vCXCL-1s for β-
arrestin2 activation is: CXCL8 (pEC50 = 9.1 nM) [high affinity for CXCR2] ≥ CXCL1 (pEC50 = 
8.3 nM) [high affinity for CXCR2] ~ Toledo (pEC50 = 8.4 nM) [high affinity for CXCR2] ~ 
E760 (pEC50 = 8.1 nM) [med-high affinity for CXCR2] ≥ C952 (7.5 nM) [high affinity for 
CXCR2] ≥ C956 [med-high affinity for CXCR2] ~ 102410 [med-low affinity for CXCR2] ~ 
100751 [med-high affinity for CXCR2] ~ C954 [med-low affinity for CXCR2] ~ TX24 [med-
low affinity for CXCR2] ≥ C952 [med-low affinity for CXCR2] ≥ TX15 [low affinity for 
CXCR2] ~ TX11 [med-high affinity for CXCR2] ~ Towne [low affinity for CXCR2]. For the 
most part, high affinity for CXCR2 or CXCR1 tracks with β-arrestin2 activation.  There are a 
few exceptions.  A medium-high affinity binder, vCXCL-1C956, did not induce β-arrestin2 while 
the low affinity, vCXCL-1Towne, did signal.  These data point to differential signalling or “biased 
agonism” that leads to differential G protein activation and β-arrestin2 potencies not directly 
correlated with receptor affinity [43]. 
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vCXCL-1s differentially induce secondary chemokine production (CCL22) 
We have observed differences in migratory ability, G protein activation, and β-arrestin2 
recruitment, but how could these phenotypes affect HCMV dissemination or pathogenesis?  
HCMV productively infects macrophages and dendritic cells and may have evolved vCXCL-1s 
to increase the recruitment of these cell types via neutrophil activation.  Macrophage derived 
chemokine (MDC), CCL22, recruits multiple immune cells, such as monocytes, dendritic cells, 
NK cells, and the Th2 subset of T cells [44].  The induction of CCL22 could have profound 
effects on the recruited cell types as well as the immune response to CMV.  Not only could these 
cells increase dissemination and/or CMV replication, CCL22 could also lead to an increase in the 
Th2 response and a down-regulation of Th1 responses [45, 46].  In fact, another UL/b’ protein, 
UL144, upregulates CCL22 and has been implicated in immune modulation (i.e., recruitment and 
activation of Th2 and Treg) [47].  In order to address whether the vCXCL-1s induce CCL22, we 
performed quantitative real-time PCR for CCL22 expression on a neutrophil-like cell line that 
over expresses CXCR2 (Figure 3.7).  vCXCL-1Toledo, vCXCL-1E760, and vCXCL-1C952, had the 
highest induction of CCL22, which is similar to CXCL1.  vCXCL-1Toledo and vCXCL-1C952 are 
high-affinity CXCR2 binders while vCXCL-1E760 belongs to the medium-high group.  Others, in 
the medium-high binding group, except vCXCL-1100751, induce CCL22. In contrast, all the 
members in the medium-low (i.e., vCXCL-1102410 and vCXCL-1C954) or low affinity group (i.e., 
vCXCL-1Tx15 and vCXCL-1Towne) except for vCXCL-1Tx24 do not induce CCL22.  As seen in 
with PBN migration, G protein and β-arrestin2 usage, high affinity binders activate downstream 
signaling and functional outcomes while the medium binders are variable and low affinity 
binders do not except for calcium flux and integrin upregulation. 
 
Discussion 
Our findings contribute to our understanding of the functions of the HCMV viral chemokines 
and their agonist activation of CXCR2. In trials where different HCMVs were inoculated into 
volunteers, role of the viral chemokines was suggested in human disease.  For example, the 
Towne strain of HCMV was less virulent than the Toledo virus in humans. Towne differs from 
the Toledo strain in the ULb’ region which contains the UL146 and UL147 viral chemokine 
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genes [48-50].  Here we have shown that Towne produces a vCXCL-1 with a low affinity for 
CXCR2, induces a lower calcium flux (with no induction at 1nm), minimal ability for 
chemotaxis, and no signaling compared with the more virulent Toledo strain vCXCL-1 (Table 
3.1).  Although this is only circumstantial evidence and one of several differences between the 
Toledo and Towne strains, vCXCL-1 differences in PBN activation are potentially contributing 
factors to the HCMV virulence observed in these studies.  Other animal models of HCMV 
pathogenesis provide a more direct link between viral chemokines and pathogenesis.  The guinea 
pig CMV (GPCMV) chemokine homolog functionally signals through the CCR1 receptor and 
plays a role in viral dissemination in vivo [51-53].  Furthermore, this virally induced 
inflammation contributes to cytomegalovirus-related inner ear injury (i.e., auditory pathology) 
[54][414].  Whether the differences in the vCXCL-1s contribute to HCMV virulence and/or 
dissemination in a similar manner to this animal model remains to be tested.  The role of 
vCXCL-1s in human pathogenesis is especially difficult without knowing the concentrations of 
these chemokines during an active HCMV infection in vivo.. 
We propose two non-exclusive models for how HCMV vCXCL-1s could function in 
vivo. One model for HCMV dissemination is the “neutrophil shuttle model”. In this model the 
neutrophil functions as a vehicle for HCMV dissemination [55].  PBNs pick up HCMV during 
neutrophil transendothelial migration and subsequently transmit infectious virus to fibroblasts 
[56, 57].  We analyzed PBN induction of calcium flux and adhesion molecules upon vCXCL-1 
treatment as indicators of neutrophil activation (Figure 3.2, 3.3), which could affect subsequent 
cell-mediated viral dissemination [58].  vCXCL-1 activated PBNs could transport virus and 
allow it to infect surrounding tissues or different cells.  Ideally we would address this shuttling 
effect directly with an antigenemia assay where vCXCL-1-treated neutrophils are assayed for 
their ability to “take up” HCMVs after migration through an infected monolayer [59].   
Unfortunately, potential differences in migration were masked by the large amount of the 
host chemokines that are secreted following HCMV infection of the fibroblast monolayer (data 
not shown).  These “background” host chemokines conceal the effects of the vCXCL1s in this in 
vitro model system.  In the present study, although the binding affinities to CXCR2 and/or 
CXCR1 were variable (Figure 3.5), all vCXCL-1s induce intracellular calcium mobilization in 
PBNs, albeit to different degrees at the concentrations tested (Figure 3.2) and upregulate β2 
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integrins on the surface of PBNs (Figure 3.3) similar to levels induced with human CXCL1 or 
CXCL8.  We speculate that vCXCL1-s from all the clades activate PBNs to increase contact with 
the endothelium.  After activation/adhesion neutrophils could be induced to migrate to the site of 
HCMV infection. To further investigate this possibility, we measured vCXCL-1-induced 
migration. The resulting chemotaxis profile did not directly correlate with receptor affinity 
(Figure 3.5C).  Although the majority medium affinity vCXCL-1s had migration only at 500nM, 
others had none at all (vCXCL-1TX24) or at lower concentrations (100nM) (vCXCL-1100751).  This 
leads us to conclude that CXCR2 binding affinities do not directly correlate with subsequent 
PBN activation, integrin upregulation or chemotaxis patterns.  This may not be too surprising as 
others have observed decreases in CXCR2 affinity while still inducing a calcium flux [60, 61] 
and elastase production [21][409]. Others have observed a complex relationship between binding 
and activation similar to our observations with our medium affinity vCXCL-1s [62].  These data 
illustrate the complexity of the CXCR2 response to agonist stimulation and its relationship with 
affinity. 
A complementary/alternate model to explain the relationship between the vCXCL-1s, 
PBNs, and HCMV is the “neutrophil amplifier model”.  This model focuses on vCXCL-1 
induction of exocytosis of neutrophilic granules or secretion of specific cytokines/chemokines.  
These inflammatory mediators could increase inflammatory responses that subsequently recruit 
other immune cells [63].  These infiltrating immune cells would provide a better vehicle for 
HCMV spread.  Macrophages and dendritic cells are better targets for HCMV infection because 
HCMV can productively infect them [64-67] while PBN infections are nonproductive [57].  The 
attraction/differentiation of myeloid cells could provide a means to infect a cell type that allows 
for more efficient virus production and/or dissemination within the host [65].  The vCXCL-1s 
induce differential CCL22 production that could have effects on myeloid cell chemotaxis.  In our 
studies, the upregulation of CCL22 correlates with the vCXCL1s’ affinity for CXCR2 (Figure 
3.7).  57% of medium-affinity vCXCL-1s induce CCL22 expression (vCXCL-1TX11, vCXCL-
1E760, vCXCL-1C956, and vCXCL-1TX24) while others did not (vCXCL-11000751, vCXCL-1102410, 
and vCXCL-1C954).  The neutrophil amplifier model would predict that those viruses that do not 
induce CCL22 in PBNs would be less pathogenic, but we have no in vivo data for this.  
Comparisons of the sequelae from HCMV congenitally infected infants, the vCXCL-1’s that 
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induce CCL22 do not correlate with clinical outcomes [17].  Our interpretation of this data 
cannot completely exclude the shuttle model our study only measured a single inflammatory 
chemokine and others chemokines/cytokines such as CCL2, CCL3, and CCL7 that were not 
measured could have a role in congenital sequelae.  
This study is the first to examine how the natural variation in the vCXCL-1s affects 
binding and PBN function.  These variants provide an opportunity to assess how changes within 
CXC chemokines affect signaling as a “biased agonist.”  Biased agonists stimulate GPCRs with 
differential signaling and functional outcomes [43].  The activation of CXCR2 initially appears 
to be redundant.  Host CXCL1, CXCL2, CXCL3, CXCL6 and CXCL8 all bind and activate 
CXCR2.  Recently Rajagopal et al [68][415] measured β-arrestin2 recruitment, cAMP signaling, 
and internalization with the different ligands on CXCR2. These related chemokines displayed a 
biased agonism for cAMP and β-arrestin2 activation. Our study found that high affinity for 
CXCR2 leads to activation of G protein dependent and independent signaling (Figure 3.6).  As 
expected, those vCXCL-1s with low affinity for CXCR2 do not initiate detectable signaling.  The 
chemokines with medium range affinity are more complex.  Some have moderate G protein 
signaling without β-arrestin2 (vCXCL-1C956) or no G protein activation with only β-arrestin2 
signaling (vCXCL-1TX11). Our data suggest a complex robustness to the viral chemokine 
response that only partially correlates with affinity.  
In conclusion our data suggest that polymorphisms in the vCXCL-1s elicit differential 
affinity to CXC chemokine receptors, which generates varying cellular responses or differential 
activation and triggering of diverse downstream signals. High affinity for CXCR2 leads to 
activation of G protein dependent and independent signaling with full activation of calcium flux, 
integrin expression, and CCL22 transcription (Table 3.1).  Those with low affinity for CXCR2 
still induce calcium flux and integrin expression while not initiating detectable signaling or 
CCL22 expression and modest PBN migration.  These data point to different thresholds for the 
different neutrophil functions.  Calcium flux and integrin expression have low thresholds where 
any degree of stimulation will activate them [69].  Other functional outcomes (i.e., migration, 
signaling, or CCL22 expression) are more complex.  Generally the extremes in affinity (i.e., high 
or low) correlate with signaling, migration, and CCL22 production.  Those with medium range 
affinity are more complex and result in varying degrees of activation [70][416].  This nuanced 
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response points to the biased agonism of these novel vCXCL-1s that could affect neutrophils and 
we speculate an effect on subsequent HCMV dissemination or virulence. 
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Appendix: Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Amino-acid alignment of the mature forms of recombinant 
vCXCL-1s and the host chemokines CXCL1 and CXCL8 with vCXCL-1 
toledo. Seven amino acid residues that are 100% conserved are indicated with 
an *. The important ELR, N-loop region, and 30s and 40s loops are indicated 
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Figure 3.2  CXCL8, CXCL1, and the different vCXCL-1s induce 
intracellular calcium mobilization on human PBNs. Changes in 
fluorescence were measured over time after exposure to different 
concentrations of chemokines (after 20 seconds at baseline as 
indicated with an arrow). Data shown are representative figures of 
three independent experiments. 
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Figure 3.3. vCXCL-1s elicit changes in surface expression of CD11a and 
CD11b. PBNs were incubated with 100 nM viral or host chemokine for 2 
hours. The shaded curve represents expression levels of integrins on 
unstimulated PBNs.  Table below lists the percentage change in mean 
fluorescence intensity (chemokine stimulated mean fluorescence 
intensity/unstimulated mean fluorescence intensity x 100).  Graphs are 
representative of three independent experiments. 
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Figure 3.4 Differential chemotaxis of PBNs to vCXCL-1s partially 
correlates with affinity. Chemotactic response of human PBNs to 500 nM 
and 100nM of CXCL8, CXCL1, or vCXCL-1s.  The chemotactic response 
was measured as fluorescence intensity of migrated PBN labeled with 
CalceinAM.  Background chemotaxis was subtracted from all samples.  Data 
shown are representative data of three independent experiments performed 
in triplicate.  
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Figure 3.5 vCXCL-1s have different binding affinities for human CXCR1 
or CXCR2.  Displacement of 
125
I-CXCL8 binding to HEK293 cells stably 
expressing human CXCR2 (A) or CXCR1 (B).  Cells were incubated with 
indicated concentration of vCXCL-1s and 200 pM 
125
I-CXCL8 for one hour at 
room temperature.  For simplicity, curves for TX11, C956, 102410, and C954 
are not shown.  (C) The average IC50 +/- standard error for all vCXCL-1s for 
either CXCR2 or CXCR1 (n=3-12).  Those with incomplete competition 
curves are indicated with a > of a predicted IC50.  Those chemokines with no 
competition at all concentrations tested are listed as >1000 IC50. 
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Figure 3.6 G protein activation and β-arrestin2 signaling correlates 
with CXCR2 affinity. vCXCL-1 chemokine induction of 
35
S-GTPγS 
binding to HEK293T membranes expressing CXCR2 (A-B).  Data are 
corrected for basal 
35
S-GTPyS binding (n=3-4).  vCXCL-1 β-arrestin2 
recruitment in PathHunter
TM
 indicator cells (C-D).  Data are expressed 
as percentage of β-galactosidase activity, in which the response to 1 µM 
CXCL8 is set to 100% (n=3-4).  
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Figure 3.7 vCXCL-1s differentially induce CCL22 expression via 
CXCR2. Neutrophil-like HL60 T2 cells were incubated in the presence of 
100 nM of the indicated vCXCL-1s or host chemokine.  Each bar represents 
the average from three separate experiments of the fold change in CCL22 
mRNA expression levels (stimulated /unstimulated cells +/- SEM).  All data 
are normalized to -actin mRNA expression levels.  A ratio of 1, indicated 
with a gray line, represents no change in expression compared to 
unstimulated cells.   
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Chemokine: 
Ca++ 
Flux 
Integrin 
Expressio
n 
Migratio
n 
G 
Protein 
Binding 
β Arrestin 
2 
CCL22 
Expressio
n 
High 
affinity 
CXCL
8 
++ ++ ++ ++ ++ +++ 
Toled
o 
++ + ++ ++ ++ ++ 
C952 ++ + ++ ++ ++ ++ 
Medium-
High 
affinity 
TX11 +/- + +/- - +/- + 
E760 + + + + ++ ++ 
C956 +/- + +/- + - + 
10075
1 
+ + + + + - 
Medium-
Low 
affinity 
10241
0 
+ + +/- + + - 
TX24 ++ + - + + + 
C954 + + +/- + + - 
Low 
affinity 
Town
e 
+/- + +/- - - - 
TX15 +/- + - - - - 
Table 3.S1 Summary of vCXCL-1 functional outcomes 
Key: +++ highest activation; ++ high activation; + activation; +/- weak 
activation; - no 
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CONCLUSION 
 
Research conclusion and summary 
Lifelong infection is a characteristic of herpesvirus infections. In the case of human 
cytomegalovirus (HCMV) healthy adults will experience lifelong latency.  However reactivation 
or primary infection causes increased morbidity and mortality in immune compromised hosts and 
congenitally infected newborns [1].  HCMV is treated with nucleoside analogs that inhibit viral 
DNA replication [2]. Current treatments exhibit varying degrees of toxicity [3].  An added 
concern is the increasing prevalence of HCMV strains that are resistant to the current antivirals.  
New therapeutics that target other steps in CMV infection should be effective against the 
aforementioned resistant strains.  CMV binds to negatively charged heparan sulfate on the cell 
surface during the attachment step of viral entry into the cell [4, 5], making it a potential target 
for anti-CMV drug development.  We targeted this step of the CMV infection lifecycle to 
develop novel therapeutics.  Chapter 1 investigates the efficacy of a protease resistant D-peptide 
against antiviral resistant HCMVs in vitro and against MCMV in vivo.  The D-peptide was 
shown to resist protease action and persist in serum compared to its L-peptide counterpart.  The 
D-peptide reduces HCMV infection by greater than 80% in all strains tested.   Furthermore our 
D-peptide reduces MCMV infection of peritoneal exudate cells when administered prior to 
infection.  When the D-peptide is combined with a currently used antiviral treatment it reduces 
the EC50 of that antiviral.  This data suggest that our D-peptide may serve as an efficacious anti-
CMV therapeutic that can be used to treat GCV resistant HCMV or in conjunction with current 
antivirals to reduce CMV infection. 
HCMV UL146 gene encodes a CXC chemokine that shows variation among different 
isolates which may contribute to their varying clinical outcomes [6].  We evaluated the role of 
HCMV UL146 encoded chemokine, vCXCL-1, in vivo using the murine model of CMV 
infection (Chapter 2).  Recombinant murine CMV (MCMV) expressing the chimpanzee CMV 
(CCMV) vCXCL-1 (vCXCL-1CCMV) and murine CXCL-1 (KC), mCXCL-1 recombinants were 
generated to test whether viral or host chemokines contribute to viral dissemination.  We 
hypothesized that vCXCL-1s are functional CXC chemokines that contribute to viral 
dissemination similar to the MCMV CC chemokine (MCK-2).  Primary dissemination is 
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comparable between the parental RM4511, which does not express a chemokine, and the 
recombinant MCMVs.  However neither MCMV vCXCL-1CCMV nor MCMV mCXCL-1 reached 
the salivary glands. SCID mice and neutrophil depletions in mice were used to determine 
whether the adaptive immune system or neutrophils were playing a role in preventing 
dissemination.  Recombinant viruses still did not disseminate in the SCID or neutrophil depleted 
mice.  Only when mice are immune ablated using cyclophosphamide are the recombinant viruses 
able to disseminate to the SG. To test whether other innate cells are involved in the 
dissemination defect, NOD-NSG mice lacking T lymphocytes, B lymphocytes, and NK cells 
were infected with recombinant viruses. In these mice, recombinant viruses disseminate.  These 
results suggest that over expression of CXC chemokines induces cells of the innate immune 
system preventing viral dissemination to the SGs.  SG dissemination is rescued when 
recombinants are co-infected with the parental RM4511.  Co-infection of the same cell at the site 
of infection is crucial for rescue of dissemination of the recombinants.  We hypothesize that co-
infection creates a resource competition resulting in less chemokine being produced.  This 
subsequently allows for dissemination to the SG. 
The HCMV genome codes for immune modulatory proteins.  One specific example is the 
UL146 gene which encodes a viral CXC chemokine, vCXCL-1.  vCXCL-1 varies greatly 
between clinical isolates and is associated with varying clinical outcomes [6,7].  vCXCL-1 
facilitates viral transmission from endothelial cells to peripheral blood neutrophils (PBNs) in 
vitro during co-culture [8, 9].  HCMV transmission requires contact between the endothelial cells 
and PBNs during which a transitory microfusion event allows the virus to infect PBNs and 
disseminate through the bloodstream.  It is suggested that HCMV encoded vCXCL-1 is 
important for recruitment of PBNs for dissemination rather than productive infection in these 
cells. This study characterized the vCXCL-1 protein from different clinical isolates in vitro 
(Chapter 3).  Because the hypervariability observed in the UL146 gene occurs within the receptor 
binding motifs, we hypothesized that variability in vCXCL-1 leads to differential activation of 
neutrophils, leading to the observed difference in HCMV pathogenesis.  vCXCL-1 proteins were 
synthesized and isolated using a baculovirus protein expression system.  Our data show that all 
vCXCL-1s bound to CXCR2 with different affinities, whereas only three bound to CXCR1.  All 
vCXCL-1s induced intracellular calcium mobilization in PBNs.  The chemotaxis of PBNs varies 
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based upon the binding affinities of vCXCL-1s to CXCR2.  Furthermore vCXCL-1s 
differentially upregulate CD11b and CD11c on the surface of PBNs.  The induction of CCL22 is 
dependent on the affinity of the CXCL-1 for CXCR2. CCL22 can attract monocytes, dendritic 
cells, and Th2 cells [10].  Once activated monocytes and dendritic cells support productive 
infection of the virus [11-13].  Additionally a Th2 response can promote viral pathogenesis by 
diminishing cytotoxic T lymphocyte responses [14, 15].  These data show that variation in 
vCXCL-1 among different isolates affects neutrophil activation which may contribute to CMV 
pathogenesis. 
Future Directions 
Chapter I: 
In this chapter we tested the D-form of a heparan sulfate (HS) binding peptide as a potential anti-
CMV therapeutic. However there are a few questions still remaining that need to be addressed to 
evaluate the full potential of these peptides as therapeutics. 
 
1. We propose that our peptide interacts with cell surface HS and that this binding is not 
indiscriminate (un-published data from Dr. Wall).  It is necessary to define the HS 
subtype that the peptide binds to. It is also important to know if the same subtype is used 
by the virus to attach to the cell during infection.   This can be done by either performing 
peptide-HS pulldown assays using biotinylated peptide or using HS arrays available at 
the University of Georgia, Complex Carbohydrate Research Center.   This data will help 
reveal the specificity of the peptides for HS subtypes.  By narrowing down which subtype 
the virus uses for attachment we can improve the peptide composition to diminish any 
side effects associated with non-specific binding.  In addition, this knowledge will be of 
great interest to CMV biologists, as it might help in understanding CMV’s cell tropism in 
vivo.  We could test this further by performing RT qPCR to determine what HS subtypes 
are expressed by cells infected with CMV. 
2. In the future, we would like to identify the sequence and structural features of the 
peptides that contribute to their function. This will help in the development and 
optimization of the peptides.  For example, from our experiments and previous study 
[16], peptides with Arg function better than peptides with Lys, even if they have the same 
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charge.  In addition, the greater the positive charge on a peptide the better it functions.  
Future experiments to test the importance of certain amino acids, charge and length can 
be carried out by using Arg and Lys containing peptides of different lengths and charges 
to identify the optimum inhibition of CMV infection.  Structural features of the peptide 
may also contribute to the peptide functionality. Secondary structure might contribute to 
the turnover and ability of the peptide to bind to the cell surface. Unpublished work in 
our lab suggests that a non-conforming secondary structure with a positive 14 charge 
reduces HCMV infection in fibroblasts when added at a less than 1μM. As a comparison 
p5R is added at 200 μM to reach the same reduction. 
3. Cationic peptides and the HS are internalized after binding [17].  It would be interesting 
to test if our peptides also get internalized and to determine when the peptide is 
internalized in order to indicate how long the peptide is efficacious.  By determining the 
turnover rate for the peptides and HS we would be able to determine the timing of peptide 
administration to inhibit viral infection. 
4. Although we did not observe any cytotoxicity for the peptide in vitro, in order to develop 
the peptides for in vivo use, toxicity assays in animals should be carried out.  Mice will be 
treated intravenously or potentially intraperitoneally with increasing concentrations of 
peptides.  Weight will be monitored in treated mice. Finally fixed and stained tissue 
analysis would be used to determine any overt toxicity, inflammation, or necrosis 
potentially caused by peptide treatment.  Peptides with modifications to increase their 
stability and bioavailability e.g. acylation and PEGylation [18] need to be tested in vitro 
before proceeding to in vivo testing.  In vitro testing would suggest whether these 
modifications alter function of our peptide.  We would treat cells with the modified 
peptides prior to infection of virus to determine if these peptides inhibit viral entry. 
5. We show that the peptides do not target the virus directly and hypothesize that there is 
less of a possibility that the virus develops resistance against these peptides. To test this 
possibility we can carry out experimental evolution studies. During these experiments we 
would infect cells with the virus in the presence of the peptides.  Then isolate the virus 
that infects even in the presence of the peptide.  This infection-isolation cycle will be 
repeated numerous times with increasing concentration of the peptides. The peptide 
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resistant variants could then be sequenced to examine what changes lead to their 
resistance to the peptide. 
6. We observed that SG MCMV was less susceptible to peptide treatment compared to the 
TC passaged MCMV. This suggests that virus grown in vivo has a different entry process.  
This specificity could be due to the cell type from which the virus is derived affecting the 
subsequent infectivity of CMV [19, 20].  The peptides could be used to elucidate the 
mechanistic difference in the infection process between viruses from the two sources. We 
can also identify which glycoprotein complexes are expressed by each virus through 
immunoblot assays. This in turn can lead to the identification of SG isolated MCMV 
entry pathways and can be exploited to understand viral pathogenesis and develop new 
therapeutics.  
 
Chapter II: 
In this chapter, we evaluated the in vivo functionality of vCXCL1 from CCMV (vCXCL-1CCMV) 
and murine host (mCXCL-1).  The following experiments would help to better define the role of 
vCXCL1 in vivo and explain the results obtained from the co-infection model. 
 
1. Generate recombinant MCMVs expressing vCXCL1s from HCMV clinical isolates. 
These recombinants could be used to investigate the role viral CXCL-1 from HCMV in 
CMV pathogenesis and dissemination.  In addition, this model will also allow us to 
investigate how the variability the chemokine affects CMV dissemination and 
pathogenesis in vivo. 
2. The vCXCL1 gene is constitutively overexpressed in our model.  Therefore, it may not 
mimic the real life scenario.  We should generate MCMV recombinants that express the 
chemokine with late gene kinetics (i.e., the mck2 promoter).  This will provide us with a 
model more closely matching HCMV chemokine expression in vivo. 
3. It is also possible that the overproduction of the chemokine leads to chemokine receptor 
desensitization [21, 22, 23-25].  This may lead to poor recruitment of cells important for 
dissemination.  To test this possibility, sorted cells from the sites of infection from mice 
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infected with either the parental or the recombinants could be tested in in vitro functional 
assays for responsiveness to chemokine stimuli. 
4. Infection of the host with multiple strains of HCMV is a very common phenomenon [26-
34].  The co-infection model can be used to investigate the co-infection phenomena 
better.  Our data shows that recombinants generate an abnormal immune response, and 
that co-infection skews the immune response to favor the dissemination of the 
recombinants.  If this is indicative of true HCMV infections then it would allow us to 
understand HCMV pathogenesis.  Generation of different recombinants that more closely 
resemble clinical strains can be used in co-infection assays to explore this further. 
 
 
Chapter III: 
In this chapter we characterized some of the functional differences in the vCXCL-1 chemokines 
from different clinical isolates. Future work focused on vCXCL-1 will help us understand its role 
in HCMV pathogenesis. 
 
1. Even when bound to the same receptor, subtle differences in the chemokine can lead to 
different signaling and cellular responses [35]. Therefore, investigating the signal 
transduction pathway more thoroughly that are induced by the different VCXCL-1 
variants will help clarify the polymorphisms at the molecular level. 
2. Our experiments show that all vCXCL1s can bind to CXCR2 and some can also bind 
CXCR1.  It is also known that these receptors induce a different downstream signaling 
cascade leading to differences in the leukocyte response [36].  Therefore it would be 
interesting to investigate the contribution of each of these receptors individually in 
functional assays (i.e., calcium flux, chemotaxis, adhesion molecule upregulation, CCL22 
induction etc.).  This can be done by using receptor blocking antibodies while performing 
these assays. Or we can exchange residues to map what is essential for the different 
signaling pathways.  This would allow us to determine how differences in vCXCL1 alter 
signaling and thus functional selectivity. 
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3. Previous studies have shown that treating fibroblasts with CXCL8 (IL-8) leads to 
increased viral replication [35, 37].   It would be interesting to investigate whether 
treating fibroblasts with the different vCXCL1s would also increase viral titers. This 
might be another mechanism by which viral chemokines contribute to the pathogenesis of 
CMV. 
4. Neutrophils can transmigrate through a monolayer of endothelial cells and pick up virus 
from the infected cells [38].  Understanding how the variability in the vCXCL1s affects 
the transmigration of neutrophils and the ability of neutrophils to pick up the virus from 
infected endothelial cells will help us understand CMV pathogenesis.  We are currently 
carrying out similar experiments in the lab by using endothelial transmigration assays in 
the presence of chemokines (data not published). 
5. We have shown that the viral chemokines upregulate the expression of adhesion 
molecules on neutrophils and propose that this aids in viral transfer to the neutrophils. 
However, it is also possible that vCXCL1s upregulate adhesion molecules (e.g. selectins, 
and integrins) on endothelial cells. This might allow for better interaction of leukocytes 
and infected endothelial cells  allowing for better transfer of the virus. 
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APPENDIX I 
MCMV ISOLATED FROM SALIVARY GLANDS BYPASSES A HEPARAN 
SULFATE BLOCKADE FOR ENTRY 
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Abstract 
Human cytomegalovirus (CMV) has a seroprevalence close 100% in developing countries.  
Infection or reactivation causes life-threatening disease in immune compromised patients and 
congenital defects following in utero infection.  MCMV is used as a model to understand the 
spread of CMV in the host.  MCMV eventually disseminates from the site of infection to the 
salivary glands (SGs).  SGs represent a crucial site for MCMV replication and transmission in 
vivo. MCMV isolated from SGs is more virulent than tissue-culture passaged virus.  We 
speculated that there are differences in cellular tropism that are related to CMV entry.   CMV 
glycoproteins gB, gM, and gN initiate entry.  gB and gM/gN are responsible for binding heparan 
sulfate proteoglycans, which consist of heparan sulfate glycosaminoglycans  attached to a protein 
core.  A previously characterized heparan sulfate binding peptide, p5+14, is effective at reducing 
tissue culture (TC) passaged MCMV infection in vitro.  In order to investigate differences in TC 
and SG isolated MCMV, we tested the peptide’s ability to reduce MCMV infection in vitro.  SG 
isolated MCMV infection in fibroblasts is only reduced by ~40% compared to the reduction of 
TC MCMV.  This suggests that SG isolated MCMV may use a different mechanism of entry that 
is not fully reliant on heparan sulfate.  One possibility is that SG MCMV could be using 
endocytosis to initiate infection. In support of this possibility we show that endocytosis inhibitors 
reduces SG MCMV infection of epithelial cells but not TC MCMV.  Together this data points to 
a unique entry mechanisms for SG vs. TC passaged MCMV that could relate to the observed 
differences in pathogenesis.  
 
 
Introduction 
Human Cytomegalovirus (HCMV) is a ubiquitous β-herpesvirus with a seroprevalence 
reaching over 90% in developing countries [1]. HCMV is the leading cause of birth defects and 
congenital infections [2]. HCMV infection in utero can lead to neurodevelopmental defects, 
including sensory neural hearing loss (SNHL) [3].  In immune compromised individuals like 
AIDS and transplantation patients, CMV infection can lead to serious complications with 
increased mortality [2]. In healthy adults however, HCMV infection is usually asymptomatic. 
HCMV establishes lifelong latency in an immune competent individual and reactivates during 
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immune suppression [2].  HCMV infects a wide range of cell types in vitro [4]. In vivo studies 
with HCMV are limited due to species specificity. Therefore, infection of mice with murine 
cytomegalovirus (MCMV) is used and accepted as an animal model for CMV studies in vivo.  
Salivary glands (SGs) represent a crucial site for MCMV replication and transmission in 
vivo [5].  MCMV isolated from SGs is more virulent than tissue-culture passaged virus [6-8]. 
However a single passage of the SG isolated MCMV on epithelial cells or fibroblasts attenuates 
this virulence [8].   There are several differences between tissue-culture passaged MCMV (TC 
MCMV) and SG isolated MCMV (SG MCMV).  There are ultrastructural differences between 
SG MCMV and TC MCMV. Electron microscopy shows that TC MCMV release progeny that 
consist of multi-capsid virions [9], while SG MCMV is characterized by one capsid per virion 
[10].  One study suggested that the virulence attributed to SG MCMV is that this virus is not 
susceptible to neutralizing antibody, yet still remains susceptible to complement [11].  Tropism 
differences are also seen in HCMV.   For example, clinically isolated HCMV displays different 
tropism than TC passaged virus [12-14].  This also holds true for MCMV.  MCMV isolated from 
SGs and other organs appears to have different tropism also [15]. 
A possible explanation for these differences come from HCMV entry mechanisms.  
Expression of different glycoprotein complexes dictates infection of host cells [16].  Both CMVs 
require expression of glycoprotein B (gB) and glycoproteins H and L (gH/gL) to infect cells 
[17,18].  HCMV and MCMV can initially enter fibroblasts using the gH/gL, and glycoprotein O 
(gH/gL/gO) trimeric complex [19,20].  Entry into endothelial and epithelial cells is mediated by 
the gH/gL/ pUL128,130,131A pentameric complex in HCMV or the gH/gL/MCK-2 trimeric 
complex in MCMV [15, 21-26].  HCMV entry into epithelial cells is accomplished using one of 
two distinct pathways: cell membrane fusion or pH-dependent endocytosis [27]. The 
gH/gL/pUL128,130,131A complex is dispensable for viral endocytosis  implying that the 
glycoprotein complexes on the virion determine tropism [28-30].  Recent studies have shown 
that both gH/gL/gO and gH/gL/MCK-2 complexes are important for MCMV spread in vivo [15] 
and that CMV tropism varies depending on the cell types from which its progeny are released 
[16, 31].  A previously characterized heparan sulfate binding peptide, p5+14, was shown to 
reduce TC MCMV and HCMV infection of fibroblasts [32].  CMV gB and gM/gN [33] gB and 
gM/gN are responsible for binding heparan sulfate proteoglycans, which is the initial step in 
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entry [33].  In this step gB and gM/gN are responsible for binding heparan sulfate proteoglycans, 
[34].  In this study we tested the hypothesis that despite differences between TC MCMV, and SG 
MCMV tropism, p5+14 blocks infection of both viruses because the initial step of binding 
HSPGs is mediated by gB and gM/gN rather than gH/gL complexes. 
 
Materials and Methods 
Cells and virus 
Mouse embryonic fibroblast (MEF) 10.1 cells and mouse mammary gland epithelial (NMuMG) 
cells (ATCC) were propagated in DMEM supplemented with 10% Fetal Clone III (FCIII), 
Penicillin/Streptomycin and L-Glutamine to a final concentration of 1%.  Tissue culture 
passaged MCMV RM4503 [37] (TC MCMV) was cultured in vitro in MEF 10.1 cells.  SG 
isolated MCMV RM4503 (SG MCMV) was harvested from BALB/c mouse SGs at 14 days post 
infection after intraperitoneal injection (1x10
6
 pfu).  SGs were homogenized then centrifuged to 
remove tissue debris.  The remaining homogenate was passed through a 70μM cell strainer 
(Falcon).  The viral titers were determined via plaque assay. All viruses were stored at -80°C 
until use. 
Plaque reduction assay 
Peptides were screened for their ability to reduce infection of TC MCMV and SG MCMV on 
MEF 10.1 cells.  Cells were seeded in a 24-well polystyrene cell culture plate and allowed to 
reach ~85% confluency.  MEF 10.1 and NMuMG cells were treated with peptide or PBS for 30 
minutes prior to the addition of virus.  After one hour of incubation with the virus and peptide, 
the mixture was removed and replaced fresh 2% carboxymethyl cellulose (CMC; Sigma Aldrich) 
and complete DMEM (CMC: DMEM).  Cells were incubated at 37°C and 5.0% CO2 for 5 days.  
Plaques were manually counted using a dissection microscope after staining with Coomassie 
blue.  Data were expressed as percent infection of PBS-treated wells.  All data were normalized 
to 100% using the peptide untreated and infected positive control data.  Peptide untreated and 
uninfected negative controls were subtracted as background.  The data are combined from one or 
more independent experiments with at least three replicates in each.  Error bars represent the 
standard deviation (SD). 
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Virus purification 
TC and SG MCMV was separated from cells and debris using centrifugation at 400xg for 10 
minutes then passed over a 70μM cell strainer.  Crude purified TC and SG MCMV were further 
purified using a sorbitol gradient as previously described [38,39].  
DNase and RNase treatment 
Crude purified SG MCMV was treated with an RNase cocktail (10U/ml A, 400U/ml TI) and 
DNase (2μg/ml)  for 2 hours at 37°C then diluted in PBS.  MEF 10.1 cells were treated with 10% 
FBS/PBS (control) or 100μM of p5+14 for 30 minutes prior to infection with ~50 pfu of RNase 
and DNase treated SG MCMV. 
Heparin treatment of TC and SG MCMV 
SG MCMV was treated with PBS, 20 μg/ml or 40 μg/ml of heparin sodium salt (Acros Organics) 
for 1 hour at 37°C then diluted in PBS.  MEF 10.1 cells were infected with ~50 pfu of treated SG 
MCMV for 1 hour.  Virus was replaced with fresh media.  
Inhibition of viral endocytosis 
In order block pH- dependent changes in the endosome 25μM of chloroquine in PBS stock was 
pre-incubated with MEF 10.1 and NMuMG cells for an hour followed by infection with ~50pfu 
of SG MCMV for 1 hour.  After absorption media was replaced. 
 
Statistical Analyses 
Data were expressed as percent infection of PBS-treated wells.  All data were normalized to 
100% using the untreated and infected positive control data.  The data are the combined data 
from two or more independent experiments with at least three replicates in each.  Error bars 
represent the standard deviation (SD). Statistical significance was calculated using a Mann-
Whitney test or 2 way ANOVA followed by Bonferroni posttests.  All analyses were performed 
using Prism 5.0 (GraphPad).   A p-value less than 0.05 was considered statistically significant. 
Significant values are labeled as *=p<0.05, **=p<0.01, ***=p<0.001, NS=non-significant 
reduction in infection.   
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Results and Discussion 
 p5+14 is less effective against SG isolated MCMV 
MEF 10.1 cells were treated with p5+14 prior to infection with SG MCMV or TC 
MCMV. p5+14 reduced infection of TC MCMV >80%, which is in agreement with our previous 
study [32].  However, p5+14 reduced SG MCMV infection by only 40% (Figure A1.1).  It is 
unclear from this result whether the SG MCMV virions or the homogenate environment 
contribute to this phenotype.  We hypothesized that the homogenate environment may contribute 
to the lack of efficacy of p5+14. 
SG homogenate does not alter p5+14 efficacy 
 In order to determine if the SG homogenate contributes to decreased efficacy of p5+14 
against SG MCMV infection, we treated MEF 10.1 with uninfected SG homogenate for 30 
minutes prior to the infection of TC MCMV.  There is no observable difference between PBS or 
homogenate treatments (Figure A1.2).  In order to remove potential p5+14 inhibitors from the 
SG MCMV prep, SG MCMV was purified over a sorbitol gradient.  There is no observable 
difference in p5+14 inhibition of the SG MCMV purified viruses and the “crude” SG MCMV 
(Figure A1.3).   p5+14 is a positively charged peptide [32].  Therefore negatively charged 
molecules like DNA and RNA in the SG homogenate may neutralize the peptide.  Although the 
sorbitol purification process separates many potential contaminants from the virions, there could 
still be DNA and RNA in the virion preps. The negative charges of these molecules could 
neutralize peptide function.  In order to address this possibility, we incubated SG MCMV with 
DNase and RNase prior to infection.   Again there is no observable difference between DNase 
and RNase treated and untreated SG MCMV (Figure A1.4).  These data suggest that the SG 
homogenate is not the reason for the lack of p5+14 efficacy against SG MCMV.  We propose 
that the virion itself and potentially the mechanism of entry differ between TC and SG MCMV.   
Heparin treatment neutralizes TC MCMV but not SG MCMV 
 Heparin and heparan sulfate are chemically related GAGs [38].  Heparin has been shown 
to reduce infection of HCMV and MCMV [39].  In order to test whether SG MCMV or TC 
MCMV use HS for entry, we incubated TC and SG MCMV with heparin sodium salt for 1 hour.  
TC MCMV infection was reduced by ~50% (Figure A1.5A).  However, SG MCMV infection 
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was not reduced after treatment with heparin sodium salt (Figure A1.5B).  These data suggest 
that either SG MCMV is not using HSPGs for entry or SG MCMV may use a HSPG subtype 
with a different chemical makeup from heparin that p5+14 preferentially binds. 
SG MCMV undergoes endocytosis to enter epithelial cells 
 As previously reported, CMV can enter epithelial cells by membrane fusion or pH-
dependent endocytosis [27].  CMV enters fibroblasts by membrane fusion [4,19,20], but there 
have been no reports of CMV entering fibroblasts via pH-dependent endocytosis.  Our data 
suggest that SG MCMV may not be utilizing HSPGs because heparin sodium salt or the HS 
binding, p5+14, does not reduce infection.  We chose to test whether SG MCMV has the ability 
to enter fibroblasts, MEF 10.1 cells, and epithelial cells, NMuMG cells, through pH-dependent 
endocytosis.  Cells were treated with 25μM chloroquine solution for 1 hour prior to infection 
with SG MCMV.  Chloroquine reduces SG MCMV infection by >40% in epithelial (Figure 
A1.6).  There is no observable difference in TC or SG MCMV entry in chloroquine treated 
fibroblasts (Figure 1A.6B).  These data suggest SG MCMV entry is partly mediated by a pH-
dependent endocytosis mechanism.  
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Conclusions and Future Directions 
SG MCMV infection is reduced by only 40% when cells are pretreated with the heparan 
sulfate binding, p5+14 peptide. It appears that this phenotype is attributed to the SG MCMV 
entry mechanism rather than the homogenate environment. A previous study indicated that 
MCMV isolated from SG MCMV uses different glycosidic linkages on the cell surface 
glycoconjugates than TC MCMV during entry [40].  Treating cells with N-
acetlyglucosaminidase or virus with N-acetylglucosamine neutralized TC MCMV infection.   
This suggests that TC MCMV binds N-acetylglucosamine.  N-acetlyglucosamine can be found at 
varying amounts in different HSPGs subtypes [41].  Meanwhile SG MCMV infection was 
inhibited by treating cells with sialidase and N-acetlyglucosaminidase [41].  From this study it 
appears SG MCMV binds to different carbohydrate moieties than its TC MCMV counterpart.  In 
future studies we would like to test whether TC or SG MCMV bind different HSPG subtypes. 
This information will map the specificity of p5+14.  Determining the specific HSPG subtypes 
targeted by p5+14 and other p5 related peptides [42, 43] will aid in our understanding which 
molecules are important for CMV entry in vivo. 
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Appendix: Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1A.1. p5+14 is less effective on SG MCMV compared 
with TC MCMV. MEF 10.1 cells were treated with PBS (control) 
or 100μM of p5+14 for 30 minutes prior to infection with either SG 
MCMV or TC MCMV. Horizontal bars ±SD represent the average 
of the percent reduction compared to PBS-treated control for three 
separate experiments with three replicates in each. 
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Figure 1A.2. SG homogenate does not reduce p5+14 efficiency. 
p5+14 was incubated with homogenate from uninfected mouse 
SG for 1 hour. MEF 10.1 cells were treated with PBS (control) or 
100μM of p5+14 + homogenate for 30 minutes prior to infection 
with TC MCMV. Horizontal bars ±SD represent the average of the 
percent reduction compared to PBS-treated control for two 
separate experiments with three replicates in each. Statistical 
significance was determined using a Kruskal-Wallis One-Way 
ANOVA test: * p-value<0.05, ** p-value<0.01, *** p-
value<0.001, NS=not significant 
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Figure 1A.3. Sorbitol virion purification does not 
alter p5+14 efficiency. MEF 10.1 cells were treated 
with PBS (control) or 100μM of p5+14 for 30 
minutes prior to infection with either SG MCMV 
isolated from a crude preparation or SG MCMV 
following a sorbitol gradient purification. Horizontal 
bars ±SD represent the average of the percent 
reduction compared to PBS-treated control  for two 
separate experiments with three replicates in each. 
Statistical significance was determined using a 
Mann-Whitney test: NS= not significant  
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Figure 1A.4.  DNase and RNase treatment  of SG MCMV 
does not alter p5+14 efficiency.  SG MCMV was treated with 
RNase cocktail (10U/ml A, 400U/ml TI) and DNase (2μg/ml)  
for 2 hours at 37°C. MEF 10.1 cells were treated with PBS 
(control) or 100μM of p5+14 for 30 minutes prior to infection 
with treated or untreated SG MCMV. Horizontal bars ±SD 
represent the average of the percent reduction compared to 
PBS-treated control  for one experiment with three replicates 
in each.  Statistical significance was determined using a 
Kruskal-Wallis One-Way ANOVA test: * p-value<0.05, ** p-
value<0.01, *** p-value<0.001, NS= not significant 
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Figure 1A.5. Heparin does not neutralize SG MCMV.  SG 
MCMV was treated with  either PBS or 20 μg/ml or 40 μg/ml of 
heparin sodium salt for 1 hour at 37°C.  MEF 10.1 cells were 
infected with  treated SG MCMV for 1 hour. Horizontal bars ±SD 
represent the average of the percent reduction compared to PBS-
treated control  for two separate experiments with three replicates in 
each. Statistical significance  was determined by a Kruskal-Wallis 
One-Way ANOVA: * p-value<0.05, ** p-value<0.01, *** p-
value<0.001, NS =not significant. 
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Figure 1A.6. Chloroquine treatment inhibits SG MCMV infection 
of epithelial cells.  MEF 10.1 (fibroblast) and NMuMG (epithelial) 
cells were treated with 25μM of chloroquine for 1 hour. Cells were 
washed once with PBS to remove any unbound virus. Cells were 
infected with either TC MCMV or SG MCMV. Horizontal bars ±SD 
represent the average of the percent reduction compared to PBS-treated 
control from two separate experiments with three replicates in each. 
Statistical significance was determined using a Mann-Whitney t-test: * 
p-value<0.05, ** p-value<0.01, *** p-value<0.001, NS = not 
significant. 
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